{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:09:31Z","timestamp":1787314171334,"version":"build-2736575974"},"update-to":[{"DOI":"10.1002\/14651858.cd014872","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000}}],"reference-count":386,"publisher":"Wiley","issue":"3","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd014872.pub2","type":"journal-article","created":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T20:16:02Z","timestamp":1742760962000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Next-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer"],"prefix":"10.1002","volume":"2025","author":[{"given":"Farasat","family":"Kazmi","sequence":"additional","affiliation":[{"name":"Department of Oncology; University of Oxford; Oxford UK"},{"name":"Department of Oncology; Norfolk and Norwich University Hospital; Norwich UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nipun","family":"Shrestha","sequence":"additional","affiliation":[{"name":"Health Evidence Synthesis, Recommendations and Impact (HESRI), School of Public Health; University of Adelaide; Adelaide, South Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tik Fung Dave","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology; Norfolk and Norwich University Hospital; Norwich UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Foord","sequence":"additional","affiliation":[{"name":"University of Oxford; Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Heesen","sequence":"additional","affiliation":[{"name":"University of Zurich; Zurich Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Booth","sequence":"additional","affiliation":[{"name":"Department of Haematology; Royal Berkshire Hospital; Reading UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dodwell","sequence":"additional","affiliation":[{"name":"Nuffield Department of Population Health; University of Oxford; Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Lord","sequence":"additional","affiliation":[{"name":"Department of Oncology; University of Oxford; Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kheng-Wei","family":"Yeoh","sequence":"additional","affiliation":[{"name":"Radiation Oncology; National Cancer Centre; Singapore Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah P","family":"Blagden","sequence":"additional","affiliation":[{"name":"Department of Oncology; University of Oxford; Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,3,24]]},"reference":[{"issue":"6","key":"10.1002\/14651858.CD014872.pub2-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0002|cit2","unstructured":"Study of AG-120 in previously treated advanced cholangiocarcinoma with IDH1 mutations (Claridhy) https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT02989857"},{"issue":"11","key":"10.1002\/14651858.CD014872.pub2-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","article-title":"Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical Claridhy trial","volume":"7","author":"Zhu","year":"2021","journal-title":"JAMA Oncology"},{"issue":"6 Suppl","key":"10.1002\/14651858.CD014872.pub2-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"LBA17","DOI":"10.1200\/JCO.2023.41.6_suppl.LBA17","article-title":"TALAPRO-2: phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","volume":"41","author":"Agarwal","year":"2023","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD014872.pub2-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"425","DOI":"10.2217\/fon-2021-0811","article-title":"Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design","volume":"18","author":"Agarwal","year":"2022","journal-title":"Future Oncology (London, England)"},{"issue":"10398","key":"10.1002\/14651858.CD014872.pub2-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"S980","DOI":"10.1016\/j.annonc.2023.09.2759","article-title":"1811P Patient-reported outcomes (PROs) in men with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) mutations receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA: results from a phase III (TALAPRO-2) study","volume":"34","author":"Fay","year":"2023","journal-title":"Annals of Oncology"},{"issue":"1","key":"10.1002\/14651858.CD014872.pub2-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41591-023-02704-x","article-title":"First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial","volume":"30","author":"Fizazi","year":"2024","journal-title":"Nature Medicine"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0009|cit9","unstructured":"Talazoparib + enzalutamide vs. enzalutamide monotherapy in mCRPC (TALAPRO-2) https:\/\/www.clinicaltrials.gov\/study\/NCT03395197"},{"issue":"10","key":"10.1002\/14651858.CD014872.pub2-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1200\/JCO.2007.14.7116","article-title":"Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer","volume":"26","author":"Amado","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0011|cit11","unstructured":"Evaluating panitumumab (ABX-EGF) plus best supportive care versus best supportive care in patients with metastatic colorectal cancer https:\/\/clinicaltrials.gov\/study\/NCT00113763"},{"issue":"13","key":"10.1002\/14651858.CD014872.pub2-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1200\/JCO.2006.08.1620","article-title":"Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer","volume":"25","author":"Van Cutsem","year":"2007","journal-title":"Journal of Clinical Oncology"},{"issue":"20","key":"10.1002\/14651858.CD014872.pub2-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer","volume":"380","author":"Andre","year":"2019","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD014872.pub2-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.annonc.2020.11.011","article-title":"Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1","volume":"32","author":"Andr\u00e9","year":"2021","journal-title":"Annals of Oncology"},{"issue":"18","key":"10.1002\/14651858.CD014872.pub2-BIB0015|cit15","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1200\/JCO.20.01139","article-title":"Patient-reported outcomes in patients with PIK3CA-mutated hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer from SOLAR-1","volume":"39","author":"Ciruelos","year":"2021","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0016|cit16","unstructured":"Study assessing the efficacy and safety of alpelisib plus fulvestrant in men and postmenopausal women with advanced breast cancer which progressed on or after aromatase inhibitor treatment. (SOLAR-1) https:\/\/clinicaltrials.gov\/study\/NCT02437318"},{"issue":"7931","key":"10.1002\/14651858.CD014872.pub2-BIB0017|cit17","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/s41586-022-05068-3","article-title":"Genomics to select treatment for patients with metastatic breast cancer","volume":"610","author":"Andre","year":"2022","journal-title":"Nature"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0018|cit18","unstructured":"High throughput technologies to drive breast cancer patients to specific phase I\/? II trials of targeted agents (SAFIR-01) https:\/\/clinicaltrials.gov\/study\/NCT01414933"},{"issue":"9940","key":"10.1002\/14651858.CD014872.pub2-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD014872.pub2-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1186\/1471-2407-11-349","article-title":"Rationale and design of DECISION: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer","volume":"11","author":"Brose","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0021|cit21","unstructured":"Nexavar versus placebo in locally advanced\/? Metastatic RAI-refractory differentiated thyroid cancer https:\/\/clinicaltrials.gov\/study\/NCT00984282"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1200\/PO.20.00372","article-title":"Molecular profiling-based assignment of cancer therapy (NCI-MPACT): a randomized multicenter phase II trial","volume":"5","author":"Chen","year":"2021","journal-title":"Journal of Clinical Oncology Precision Oncology"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0023|cit23","unstructured":"NCI-MPACT study to compare effects of targeted drugs on tumor gene variations https:\/\/clinicaltrials.gov\/study\/NCT01827384"},{"issue":"18","key":"10.1002\/14651858.CD014872.pub2-BIB0024|cit24","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1200\/JCO.22.01649","article-title":"Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer","volume":"41","author":"Chi","year":"2023","journal-title":"Journal of Clinical Oncology"},{"issue":"6 Suppl","key":"10.1002\/14651858.CD014872.pub2-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1200\/JCO.2022.40.6_suppl.012","article-title":"Phase 3 MAGNITUDE study: first results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations","volume":"40","author":"Chi","year":"2022","journal-title":"Journal of Clinical Oncology"},{"issue":"6 Suppl","key":"10.1002\/14651858.CD014872.pub2-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1200\/JCO.2023.41.6_suppl.170","article-title":"Niraparib (NIRA) with abiraterone acetate and prednisone (AAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: second interim analysis (IA2) of MAGNITUDE","volume":"41","author":"Efstathiou","year":"2023","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0027|cit27","unstructured":"A study of niraparib in combination with abiraterone acetate and prednisone versus abiraterone acetate and prednisone for treatment of participants with metastatic prostate cancer (MAGNITUDE) https:\/\/clinicaltrials.gov\/study\/NCT03748641"},{"issue":"4","key":"10.1002\/14651858.CD014872.pub2-BIB0028|cit28","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.eururo.2024.09.003","article-title":"Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer and BRCA1\/2 gene alterations: final analysis from the randomized phase 3 MAGNITUDE trial","volume":"42","author":"Rathkopf","year":"2024","journal-title":"European Urology"},{"issue":"6","key":"10.1002\/14651858.CD014872.pub2-BIB0029|cit29","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1093\/annonc\/mdw136","article-title":"Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX","volume":"27","author":"Ciardiello","year":"2016","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0030|cit30","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/S1470-2045(18)30365-6","article-title":"Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"7","author":"Clarke","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0031|cit31","unstructured":"Ph II study to evaluate olaparib with abiraterone in treating metastatic castration resistant prostate cancer https:\/\/clinicaltrials.gov\/study\/NCT01972217"},{"issue":"9","key":"10.1002\/14651858.CD014872.pub2-BIB0032|cit32","doi-asserted-by":"publisher","first-page":"EVIDoa2200043","DOI":"10.1056\/EVIDoa2200043","article-title":"Abiraterone and olaparib for metastatic castration-resistant prostate cancer","volume":"1","author":"Clarke","year":"2022","journal-title":"NEJM Evidence"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0033|cit33","unstructured":"Study on olaparib plus abiraterone as first-line therapy in men with metastatic castration-resistant prostate cancer https:\/\/classic.clinicaltrials.gov\/ct2\/show\/results\/NCT03732820"},{"issue":"6","key":"10.1002\/14651858.CD014872.pub2-BIB0034|cit34","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1016\/j.euo.2024.03.006","article-title":"Tolerability of olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: further results from the phase 3 Propel trial","volume":"7","author":"Saad","year":"2024","journal-title":"European Urology Oncology"},{"issue":"10","key":"10.1002\/14651858.CD014872.pub2-BIB0035|cit35","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","article-title":"Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial","volume":"24","author":"Saad","year":"2023","journal-title":"Lancet Oncology"},{"issue":"7","key":"10.1002\/14651858.CD014872.pub2-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/S1470-2045(19)30150-0","article-title":"Quizartinib versus salvage chemotherapy in relapsed or refractory <em>FLT3<\/em>-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial","volume":"20","author":"Cortes","year":"2019","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0037|cit37","unstructured":"(quantum-R): an open-label study of quizartinib monotherapy vs. Salvage chemotherapy in acute myeloid leukemia (AML) subjects who are FLT3-ITD positive https:\/\/clinicaltrials.gov\/study\/NCT02039726"},{"issue":"5","key":"10.1002\/14651858.CD014872.pub2-BIB0038|cit38","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.eururo.2022.05.019","article-title":"Overall survival update for patients with metastatic castration-resistant prostate cancer treated with capivasertib and docetaxel in the phase 2 Procaid clinical trial","volume":"82","author":"Crabb","year":"2022","journal-title":"European Urology"},{"issue":"3","key":"10.1002\/14651858.CD014872.pub2-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1200\/JCO.20.01576","article-title":"Pan-AKT inhibitor capivasertib with docetaxel and prednisolone in metastaticcastration-resistant prostate cancer: a randomized, placebo-controlled phase II trial (Procaid)","volume":"39","author":"Crabb","year":"2021","journal-title":"Journal of Clinical Oncology"},{"issue":"6 Suppl","key":"10.1002\/14651858.CD014872.pub2-BIB0040|cit40","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1200\/JCO.2022.40.6_suppl.108","article-title":"Updated overall survival (OS) analysis for ProCAID: a randomized, double-blind, placebo-controlled phase II trial of capivasertib with docetaxel versus docetaxel alone in metastatic castration-sensitive prostate cancer (mCRPC)","volume":"40","author":"Crabb","year":"2022","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0041|cit41","unstructured":"Randomised,double blind phase II study in MCRPC of AZD5363 in combination with DP chemotherapy (Procaid) https:\/\/clinicaltrials.gov\/study\/NCT02121639"},{"issue":"22","key":"10.1002\/14651858.CD014872.pub2-BIB0042|cit42","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"De Bono","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"24","key":"10.1002\/14651858.CD014872.pub2-BIB0043|cit43","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","article-title":"Survival with olaparib in metastatic castration-resistant prostate cancer","volume":"383","author":"Hussain","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD014872.pub2-BIB0044|cit44","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1200\/JCO.23.00339","article-title":"Olaparib for the treatment of patients with metastatic castration-resistant prostate cancer and alterations in BRCA1 and\/or BRCA2 in the Profound trial","volume":"42","author":"Mateo","year":"2024","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0045|cit45","unstructured":"Study of olaparib (lynparza) versus enzalutamide or abiraterone acetate in men with metastatic castration-resistant prostate cancer (Profound study) https:\/\/clinicaltrials.gov\/study\/NCT02987543"},{"issue":"4","key":"10.1002\/14651858.CD014872.pub2-BIB0046|cit46","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.eururo.2020.09.024","article-title":"Efficacy of PARP inhibition in metastatic castration-resistant prostate cancer is very different with non-BRCA DNA repair alterations: reconstructing prespecified endpoints for cohort B from the phase 3 Profound trial of olaparib","volume":"79","author":"Stopsack","year":"2021","journal-title":"European Urology"},{"issue":"3","key":"10.1002\/14651858.CD014872.pub2-BIB0047|cit47","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S1470-2045(22)00017-1","article-title":"Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial","volume":"23","author":"Thiery-Vuillemin","year":"2022","journal-title":"Lancet Oncology"},{"issue":"2","key":"10.1002\/14651858.CD014872.pub2-BIB0048|cit48","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1182\/blood.2021014901","article-title":"Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed\/refractory AML: a randomized phase 3 trial","volume":"141","author":"De Botton","year":"2023","journal-title":"Blood"},{"issue":"16 Suppl","key":"10.1002\/14651858.CD014872.pub2-BIB0049|cit49","doi-asserted-by":"publisher","first-page":"7032","DOI":"10.1200\/JCO.2022.40.16_suppl.7032","article-title":"Health-related quality of life (HRQoL) with enasidenib versus conventional care regimens in older patients with late-stage mutant-IDH2 relapsed or refractory acute myeloid leukemia (R\/R AML)","volume":"40","author":"Dinardo","year":"2022","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0050|cit50","unstructured":"An efficacy and safety study of AG-221 (CC-90007) versus conventional care regimens in older subjects with late stage acute myeloid leukemia harboring an isocitrate dehydrogenase 2 mutation (IDHENTIFY) https:\/\/clinicaltrials.gov\/study\/NCT02577406"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0051|cit51","doi-asserted-by":"publisher","first-page":"175883592110596","DOI":"10.1177\/17588359211059601","article-title":"Safety and efficacy of veliparib plus carboplatin\/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline BRCA1\/2 mutations and hormone receptor status from the phase-3 BROCADE3 trial","volume":"13","author":"Ayoub","year":"2021","journal-title":"Therapeutic Advances in Medical Oncology"},{"issue":"10","key":"10.1002\/14651858.CD014872.pub2-BIB0052|cit52","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/S1470-2045(20)30447-2","article-title":"Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Dieras","year":"2020","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0053|cit53","doi-asserted-by":"publisher","first-page":"113580","DOI":"10.1016\/j.ejca.2024.113580","article-title":"Veliparib with carboplatin and paclitaxel in BRCA mutated advanced breast cancer (BROCADE3): final overall survival results from a randomized phase 3 trial","volume":"200","author":"Dieras","year":"2024","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0054|cit54","unstructured":"A phase 3 randomized, placebo-controlled trial of carboplatin and paclitaxel with or without veliparib (ABT-888) in HER2-negative metastatic or locally advanced unresectable BRCA-associated breast cancer https:\/\/clinicaltrials.gov\/study\/NCT02163694"},{"issue":"7","key":"10.1002\/14651858.CD014872.pub2-BIB0055|cit55","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/jama.2024.10613","article-title":"Ivonescimab plus chemotherapy in non-small cell lung cancer with EGFR variant: a randomized clinical trial","volume":"332","author":"HARMONi-A Study Investigators","year":"2024","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0056|cit56","unstructured":"Phase 3 clinical study of AK112 for NSCLC patients https:\/\/clinicaltrials.gov\/study\/NCT05184712"},{"issue":"6 Suppl","key":"10.1002\/14651858.CD014872.pub2-BIB0057|cit57","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1200\/JCO.2023.41.6_suppl.18","article-title":"Rucaparib for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 interim overall survival and efficacy of rucaparib vs docetaxel or second-generation androgen pathway inhibitor therapy","volume":"41","author":"Bryce","year":"2023","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1002\/14651858.CD014872.pub2-BIB0058|cit58","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1056\/NEJMoa2214676","article-title":"Rucaparib or physician's choice in metastatic prostate cancer","volume":"388","author":"Fizazi","year":"2023","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0059|cit59","unstructured":"A study of rucaparib versus physician's choice of therapy in participants with metastatic castration-resistant prostate cancer and homologous recombination gene deficiency (TRITON3) https:\/\/clinicaltrials.gov\/study\/NCT02975934?tab=results"},{"issue":"6 Suppl","key":"10.1002\/14651858.CD014872.pub2-BIB0060|cit60","doi-asserted-by":"publisher","first-page":"TPS389","DOI":"10.1200\/JCO.2018.36.6_suppl.TPS389","article-title":"TRITON3: an international, randomized, open-label, phase III study of the PARP inhibitor rucaparib vs. physician's choice of therapy for patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD)","volume":"36","author":"Ryan","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"10.1002\/14651858.CD014872.pub2-BIB0061|cit61","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S1470-2045(22)00284-4","article-title":"Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial","volume":"23","author":"Howell","year":"2022","journal-title":"Lancet Oncology"},{"issue":"3","key":"10.1002\/14651858.CD014872.pub2-BIB0062|cit62","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S1470-2045(19)30817-4","article-title":"Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial","volume":"21","author":"Jones","year":"2020","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0063|cit63","unstructured":"Fulvestrant +\/? - akt inhibition in advanced aromatase inhibitor resistant breast cancer (FAKTION) https:\/\/clinicaltrials.gov\/study\/NCT01992952"},{"issue":"4","key":"10.1002\/14651858.CD014872.pub2-BIB0064|cit64","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/S1470-2045(22)00122-X","article-title":"Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial","volume":"23","author":"Kristeleit","year":"2022","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0065|cit65","unstructured":"ARIEL4: a study of rucaparib versus chemotherapy BRCA mutant ovarian, fallopian tube, or primary peritoneal cancer patients https:\/\/clinicaltrials.gov\/study\/NCT02855944"},{"issue":"Suppl 7","key":"10.1002\/14651858.CD014872.pub2-BIB0066|cit66","doi-asserted-by":"publisher","first-page":"S235","DOI":"10.1016\/annonc\/annonc1054","article-title":"Overall survival results from ARIEL4: a phase III study assessing rucaparib vs chemotherapy in patients with advanced, relapsed ovarian carcinoma and a deleterious BRCA1\/2 mutation","volume":"33","author":"Oza","year":"2022","journal-title":"Annals of Oncology"},{"issue":"36","key":"10.1002\/14651858.CD014872.pub2-BIB0067|cit67","doi-asserted-by":"publisher","first-page":"4305","DOI":"10.1200\/JCO.24.00683","article-title":"Cediranib and olaparib combination compared with cediranib or olaparib alone, or chemotherapy in platinum-resistant or primary platinum-refractory ovarian cancer: NRG-GY005","volume":"42","author":"Lee","year":"2024","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0068|cit68","unstructured":"Testing the combination of cediranib and olaparib in comparison to each drug alone or other chemotherapy in recurrent platinum-resistant ovarian cancer https:\/\/www.clinicaltrials.gov\/study\/NCT02502266"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD014872.pub2-BIB0069|cit69","doi-asserted-by":"publisher","first-page":"11515","DOI":"10.1200\/JCO.2017.35.15_suppl.11515","article-title":"SHIVA: randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer - overall survival (OS) analysis","volume":"35","author":"Dureau","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1002\/14651858.CD014872.pub2-BIB0070|cit70","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1158\/1078-0432.CCR-19-2170","article-title":"TBCRC 032 IB\/II multicenter study: molecular insights to AR antagonist and PI3K inhibitor efficacy in patients with AR+ metastatic triple-negative breast cancer","volume":"26","author":"Lehmann","year":"2019","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0071|cit71","unstructured":"Taselisib and enzalutamide in treating patients with androgen receptor positive triple-negative metastatic breast cancer https:\/\/clinicaltrials.gov\/study\/NCT02457910"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD014872.pub2-BIB0072|cit72","doi-asserted-by":"publisher","first-page":"11515","DOI":"10.1200\/JCO.2017.35.15_suppl.11515","article-title":"SHIVA: randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer - overall survival (OS) analysis","volume":"35","author":"Dureau","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"13","key":"10.1002\/14651858.CD014872.pub2-BIB0073|cit73","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/S1470-2045(15)00188-6","article-title":"Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial","volume":"16","author":"Le Tourneau","year":"2015","journal-title":"Lancet Oncology"},{"issue":"1","key":"10.1002\/14651858.CD014872.pub2-BIB0074|cit74","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/bjc.2014.211","article-title":"Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial","volume":"111","author":"Le Tourneau","year":"2014","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0075|cit75","unstructured":"A randomized phase II trial comparing therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer (SHIVA) https:\/\/clinicaltrials.gov\/study\/NCT01771458"},{"issue":"9","key":"10.1002\/14651858.CD014872.pub2-BIB0076|cit76","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1093\/annonc\/mdy257","article-title":"Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1\/2 mutation: patient-reported outcomes from the EMBRACA phase III trial","volume":"29","author":"Ettl","year":"2018","journal-title":"Annals of Oncology"},{"issue":"3","key":"10.1002\/14651858.CD014872.pub2-BIB0077|cit77","doi-asserted-by":"publisher","first-page":"e439","DOI":"10.1634\/theoncologist.2019-0493","article-title":"Talazoparib in patients with a germline BRCA-mutated advanced breast cancer: detailed safety analyses from the phase III EMBRACA trial","volume":"25","author":"Hurvitz","year":"2020","journal-title":"Oncologist"},{"issue":"11","key":"10.1002\/14651858.CD014872.pub2-BIB0078|cit78","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1016\/j.annonc.2020.08.2098","article-title":"Talazoparib versus chemotherapy in patients with germline BRCA1\/2 mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial","volume":"31","author":"Litton","year":"2020","journal-title":"Annals of Oncology"},{"issue":"8","key":"10.1002\/14651858.CD014872.pub2-BIB0079|cit79","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"New England Journal"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0080|cit80","unstructured":"A study evaluating talazoparib (BMN 673), a PARP inhibitor, in advanced and\/or metastatic breast cancer patients with BRCA mutation (EMBRACA study) (EMBRACA) https:\/\/clinicaltrials.gov\/study\/NCT01945775"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0081|cit81","doi-asserted-by":"publisher","first-page":"S1285","DOI":"10.1016\/j.annonc.2023.10.039","article-title":"LBA45 overall survival (OS) outcomes from NRG-GY004, a phase III study comparing single-agent olaparib or combination cediranib and olaparib to platinum (Plat) based chemotherapy in recurrent Plat-sensitive ovarian cancer (OvCa)","volume":"34","author":"Liu","year":"2023","journal-title":"Annals of Oncology"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD014872.pub2-BIB0082|cit82","doi-asserted-by":"publisher","first-page":"6003","DOI":"10.1200\/JCO.2020.38.15_suppl.6003","article-title":"A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer","volume":"38","author":"Liu","year":"2020","journal-title":"Journal of Clincal Oncology"},{"issue":"19","key":"10.1002\/14651858.CD014872.pub2-BIB0083|cit83","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1200\/JCO.21.02011","article-title":"Olaparib with or without cediranib versus platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer (NRG-GY004): a randomized, open-label, phase III trial","volume":"40","author":"Liu","year":"2022","journal-title":"Journal of Clincal Oncology"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0084|cit84","unstructured":"Testing the use of a single drug (olaparib) or the combination of two drugs (cediranib and olaparib) compared to the usual chemotherapy for women with platinum sensitive ovarian, fallopian tube, or primary peritoneal cancer https:\/\/www.clinicaltrials.gov\/study\/NCT02446600"},{"issue":"21","key":"10.1002\/14651858.CD014872.pub2-BIB0085|cit85","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","article-title":"Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma","volume":"389","author":"Loriot","year":"2023","journal-title":"New England Journal of Medicine"},{"issue":"17 Suppl","key":"10.1002\/14651858.CD014872.pub2-BIB0086|cit86","doi-asserted-by":"publisher","first-page":"LBA4619","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA4619","article-title":"Phase 3 THOR study: results of erdafitinib (Erda) versus chemotherapy (Chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt)","volume":"41","author":"Loriot","year":"2023","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0087|cit87","unstructured":"A study of erdafitinib compared with vinflunine or docetaxel or pembrolizumab in participants with advanced urothelial cancer and selected fibroblast growth factor receptor (FGFR) gene aberrations (THOR) https:\/\/clinicaltrials.gov\/study\/NCT03390504"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0088|cit88","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0089|cit89","unstructured":"AZD9291 (osimertinib) versus platinum-based doublet-chemotherapy in locally advanced or metastatic non-small cell lung cancer (AURA3) https:\/\/clinicaltrials.gov\/study\/NCT02151981"},{"issue":"11","key":"10.1002\/14651858.CD014872.pub2-BIB0090|cit90","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1016\/j.annonc.2020.08.2100","article-title":"Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis","volume":"31","author":"Papadimitrakopoulou","year":"2020","journal-title":"Annals of Oncology"},{"issue":"24","key":"10.1002\/14651858.CD014872.pub2-BIB0091|cit91","doi-asserted-by":"publisher","first-page":"5469","DOI":"10.1158\/1078-0432.CCR-15-0526","article-title":"Analysis of KRAS\/NRAS mutations in a phase III study of panitumumab with FOLFIRI compared with FOLFIRI alone as second-line treatment for metastatic colorectal cancer","volume":"21","author":"Peeters","year":"2015","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"10.1002\/14651858.CD014872.pub2-BIB0092|cit92","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1093\/annonc\/mdt523","article-title":"Final results from a randomized phase 3 study of FOLFIRI \u00b1 panitumumab for second-line treatment of metastatic colorectal cancer","volume":"25","author":"Peeters","year":"2014","journal-title":"Annals of Oncology"},{"issue":"31","key":"10.1002\/14651858.CD014872.pub2-BIB0093|cit93","doi-asserted-by":"publisher","first-page":"4706","DOI":"10.1200\/JCO.2009.27.6055","article-title":"Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer","volume":"28","author":"Peeters","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD014872.pub2-BIB0094|cit94","doi-asserted-by":"publisher","first-page":"TPS5598","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS5598","article-title":"SOLO3: a randomized phase III trial of olaparib versus chemotherapy in platinum-sensitive relapsed ovarian cancer patients with a germline BRCA1\/2 mutation (gBRCAm)","volume":"34","author":"Lowe","year":"2016","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0095|cit95","unstructured":"Olaparib treatment in relapsed germline breast cancer susceptibility gene (BRCA) mutated ovarian cancer patients who have progressed at least 6 months after last platinum treatment and have received at least 2 prior platinum treatments (SOLO3) https:\/\/clinicaltrials.gov\/study\/NCT02282020"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0096|cit96","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1016\/S0090-8258(22)01244-6","article-title":"Final overall survival results from SOLO3: phase III trial assessing olaparib monotherapy versus non-platinum chemotherapy in heavily pretreated patients with germline BRCA1 - and\/or BRCA2-mutated platinum-sensitive relapsed ovarian cancer (026)","volume":"166","author":"Penson","year":"2022","journal-title":"Gynecologic Oncology"},{"issue":"11","key":"10.1002\/14651858.CD014872.pub2-BIB0097|cit97","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1200\/JCO.19.02745","article-title":"Olaparib versus nonplatinum chemotherapy in patients with platinum-sensitive relapsed ovarian cancer and a germline BRCA1\/2 mutation (SOLO3): a randomized phase III trial","volume":"38","author":"Penson","year":"2020","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0098|cit98","unstructured":"A study of ASP2215 versus salvage chemotherapy in patients with relapsed or refractory acute myeloid leukemia (AML) with FMS-like tyrosine kinase (FLT3) mutation Available from https:\/\/clinicaltrials.gov\/study\/NCT02421939"},{"issue":"23","key":"10.1002\/14651858.CD014872.pub2-BIB0099|cit99","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.1182\/blood.2021011583","article-title":"Follow-up of patients with R\/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial","volume":"139","author":"Perl","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1002\/14651858.CD014872.pub2-BIB0100|cit100","doi-asserted-by":"publisher","first-page":"265.e1","DOI":"10.1016\/j.jtct.2022.12.006","article-title":"Outcomes in patients with FLT3-mutated relapsed\/ refractory acute myelogenous leukemia who underwent transplantation in the phase 3 ADMIRAL trial of gilteritinib versus salvage chemotherapy","volume":"29","author":"Perl","year":"2023","journal-title":"Transplantation and Cellular Therapy"},{"issue":"18","key":"10.1002\/14651858.CD014872.pub2-BIB0101|cit101","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"New England Journal Medicine"},{"issue":"5","key":"10.1002\/14651858.CD014872.pub2-BIB0102|cit102","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1080\/10428194.2023.2186731","article-title":"Patient-reported outcomes from the phase 3 ADMIRAL trial in patients with FLT3-mutated\/relapsed\/refractory AML","volume":"64","author":"Ritchie","year":"2023","journal-title":"Leukemia & Lymphoma"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0103|cit103","unstructured":"Assessment of the efficacy and safety of olaparib monotherapy versus physicians choice chemotherapy in the treatment of metastatic breast cancer patients with germline BRCA1\/? 2 mutations (Olympiad) https:\/\/clinicaltrials.gov\/study\/NCT02000622"},{"issue":"6","key":"10.1002\/14651858.CD014872.pub2-BIB0104|cit104","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD014872.pub2-BIB0105|cit105","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ejca.2023.01.031","article-title":"OlympiAD extended follow-up for overall survival and safety: olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer","volume":"184","author":"Robson","year":"2023","journal-title":"European Journal of Cancer"},{"issue":"2","key":"10.1002\/14651858.CD014872.pub2-BIB0106|cit106","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1470-2045(22)00739-2","article-title":"Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"24","author":"Rodler","year":"2023","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0107|cit107","unstructured":"Phase II randomized placebo-controlled trial of cisplatin with or without ABT-888 (veliparib) in metastatic triple-negative breast cancer (TNBC) and\/or BRCA mutation-associated breast cancer, with or without brain metastases https:\/\/www.swog.org\/clinical-trials\/s1416"},{"issue":"29","key":"10.1002\/14651858.CD014872.pub2-BIB0108|cit108","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","article-title":"Cabozantinib in progressive medullary thyroid cancer","volume":"31","author":"Elisei","year":"2013","journal-title":"Journal of Clincal Oncology"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0109|cit109","unstructured":"Efficacy of XL184 (cabozantinib) in advanced medullary thyroid cancer (EXAM) https:\/\/clinicaltrials.gov\/study\/NCT00704730"},{"issue":"11","key":"10.1002\/14651858.CD014872.pub2-BIB0110|cit110","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1093\/annonc\/mdx479","article-title":"Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma","volume":"28","author":"Schlumberger","year":"2017","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0111|cit111","unstructured":"Study of efficacy and safety of buparlisib (BKM120) plus paclitaxel versus placebo plus paclitaxel in recurrent or metastatic head and neck cancer previously pre-treated with a platinum therapy https:\/\/clinicaltrials.gov\/study\/NCT01852292?tab=history"},{"issue":"3","key":"10.1002\/14651858.CD014872.pub2-BIB0112|cit112","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S1470-2045(17)30064-5","article-title":"Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial","volume":"18","author":"Soulieres","year":"2017","journal-title":"Lancet Oncology"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD014872.pub2-BIB0113|cit113","doi-asserted-by":"publisher","first-page":"6008","DOI":"10.1200\/JCO.2016.34.15_suppl.6008","article-title":"BERIL-1: A phase II, placebo-controlled study of buparlisib (BKM120) plus paclitaxel in patients with platinum-pretreated recurrent\/metastatic head and neck squamous cell carcinoma (HNSCC)","volume":"34","author":"Soulieres","year":"2016","journal-title":"Journal of Clincal Oncology"},{"issue":"11","key":"10.1002\/14651858.CD014872.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1158\/1078-0432.CCR-17-2644","article-title":"Molecular alterations and buparlisib efficacy in patients with squamous cell carcinoma of the head and neck: biomarker analysis from BERIL-1","volume":"24","author":"Soulieres","year":"2018","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0115|cit115","unstructured":"Initiative for molecular profiling in advanced cancer therapy (IMPACT) trial, an umbrella protocol https:\/\/clinicaltrials.gov\/study\/NCT00851032"},{"issue":"1","key":"10.1002\/14651858.CD014872.pub2-BIB0116|cit116","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-019-0835-1","article-title":"Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine","volume":"12","author":"Tsimberidou","year":"2019","journal-title":"Journal of Hematology & Oncology"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0117|cit117","unstructured":"Capivasertib+fulvestrant vs placebo + fulvestrant as treatment for locally advanced (inoperable) or metastatic HR+\/HER2- breast cancer (Capitello-291) https:\/\/clinicaltrials.gov\/study\/NCT04305496"},{"issue":"9","key":"10.1002\/14651858.CD014872.pub2-BIB0118|cit118","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/S1470-2045(24)00373-5","article-title":"Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial","volume":"25","author":"Oliveira","year":"2024","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0119|cit119","doi-asserted-by":"publisher","first-page":"S388","DOI":"10.1016\/j.annonc.2020.08.452","article-title":"350TiP A phase III trial of capivasertib and fulvestrant versus placebo and fulvestrant in patients with HR+\/HER2-breast cancer (CAPItello-291)","volume":"31","author":"Turner","year":"2020","journal-title":"Annals of Oncology"},{"issue":"22","key":"10.1002\/14651858.CD014872.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","article-title":"Capivasertib in hormone receptor-positive advanced breast cancer","volume":"388","author":"Turner","year":"2023","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0121|cit121","unstructured":"A study of ASP2215 versus salvage chemotherapy in patients with relapsed or refractory acute myeloid leukemia (AML) with FLT3 mutation https:\/\/clinicaltrials.gov\/study\/NCT03182244?term=NCT03182244&rank=1"},{"issue":"Supplement 1","key":"10.1002\/14651858.CD014872.pub2-BIB0122|cit122","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1182\/blood-2021-145436","article-title":"Gilteritinib versus salvage chemotherapy for relapsed\/refractory FLT3-mutated acute myeloid leukemia: a phase 3, randomized, multicenter, open-label trial in Asia","volume":"138","author":"Wang","year":"2021","journal-title":"Blood"},{"issue":"11","key":"10.1002\/14651858.CD014872.pub2-BIB0123|cit123","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1038\/s41375-024-02382-9","article-title":"Phase 3 study of gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed\/refractory FLT3-mutated acute myeloid leukemia","volume":"38","author":"Wang","year":"2024","journal-title":"Leukemia"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0124|cit124","doi-asserted-by":"publisher","first-page":"ix92","DOI":"10.1093\/annonc\/mdy437.019","article-title":"A phase III randomized study of gilteritinib versus salvage chemotherapy in FLT3 mutation-positive subjects with relapsed or refractory acute myeloid leukemia","volume":"29","author":"Wang","year":"2018","journal-title":"Annals of Oncology"},{"issue":"5","key":"10.1002\/14651858.CD014872.pub2-BIB0125|cit125","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/s1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncology"},{"issue":"3","key":"10.1002\/14651858.CD014872.pub2-BIB0126|cit126","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S1470-2045(13)70611-9","article-title":"Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01\/UNICANCER)","volume":"15","author":"Andr\u00e9","year":"2014","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0127|cit127","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ygyno.2023.03.013","article-title":"DKK1 is a predictive biomarker for response to DKN-01: results of a phase 2 basket study in women with recurrent endometrial carcinoma","volume":"172","author":"Arend","year":"2023","journal-title":"Gynecologic Oncology"},{"issue":"12","key":"10.1002\/14651858.CD014872.pub2-BIB0128|cit128","doi-asserted-by":"publisher","first-page":"100870","DOI":"10.1016\/j.tranon.2020.100870","article-title":"Therapeutic relevance of molecular screening program in patients with metastatic sarcoma: analysis from the ProfiLER 01 trial","volume":"13","author":"Arnaud-Coffin","year":"2020","journal-title":"Translational Oncology"},{"issue":"4","key":"10.1002\/14651858.CD014872.pub2-BIB0129|cit129","doi-asserted-by":"publisher","first-page":"287","DOI":"10.2217\/pme-2018-0056","article-title":"Using clinical genomic sequencing to guide personalized cancer therapy in China","volume":"16","author":"Bai","year":"2019","journal-title":"Personalized Medicine"},{"issue":"1","key":"10.1002\/14651858.CD014872.pub2-BIB0130|cit130","first-page":"74","article-title":"Molecular control of treatment with imatinib in patients with chronic myeloif leukemia","volume":"46","author":"Balatzenko","year":"2010","journal-title":"Clinical and Transfusion Haematology"},{"issue":"12","key":"10.1002\/14651858.CD014872.pub2-BIB0131|cit131","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/S1470-2045(17)30682-4","article-title":"Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Bang","year":"2017","journal-title":"Lancet Oncology"},{"issue":"4","key":"10.1002\/14651858.CD014872.pub2-BIB0132|cit132","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s11523-018-0576-z","article-title":"Targeted next-generation sequencing in men with metastatic prostate cancer: a pilot study","volume":"13","author":"Barata","year":"2018","journal-title":"Targeted Oncology"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0133|cit133","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1200\/PO.20.00445","article-title":"Genomic profiling of premenopausal HR+ and HER2- metastatic breast cancer by circulating tumor DNA and association of genetic alterations with therapeutic response to endocrine therapy and ribociclib","volume":"5","author":"Bardia","year":"2021","journal-title":"Journal of Clinical Oncology Precision Oncology"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0134|cit134","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1200\/PO.22.00165","article-title":"Phase II study of afatinib in patients with tumors with human epidermal growth factor receptor 2-activating mutations: results from the National Cancer Institute - molecular analysis for therapy choice ECOG-ACRIN trial (EAY131) subprotocol EAY131-B","volume":"172","author":"Bedard","year":"2022","journal-title":"Journal of Clinical Oncology Precision Oncology"},{"issue":"1","key":"10.1002\/14651858.CD014872.pub2-BIB0135|cit135","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13073-021-00897-9","article-title":"Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial","volume":"13","author":"Bertucci","year":"2021","journal-title":"Genome Medicine"},{"issue":"9","key":"10.1002\/14651858.CD014872.pub2-BIB0136|cit136","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/S2352-3026(17)30143-6","article-title":"Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trials","volume":"4","author":"Bhutani","year":"2017","journal-title":"Lancet Haematology"},{"issue":"9","key":"10.1002\/14651858.CD014872.pub2-BIB0137|cit137","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.3390\/cancers14092275","article-title":"Molecular profiles of advanced urological cancers in the PERMED-01 precision medicine clinical trial","volume":"14","author":"Billon","year":"2022","journal-title":"Cancers"},{"issue":"23","key":"10.1002\/14651858.CD014872.pub2-BIB0138|cit138","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1182\/blood-2017-05-785683","article-title":"First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia","volume":"130","author":"Boidol","year":"2017","journal-title":"Blood"},{"issue":"10","key":"10.1002\/14651858.CD014872.pub2-BIB0139|cit139","doi-asserted-by":"publisher","first-page":"e0238795","DOI":"10.1371\/journal.pone.0238795","article-title":"Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine","volume":"15","author":"Bories","year":"2020","journal-title":"PloS One"},{"issue":"8","key":"10.1002\/14651858.CD014872.pub2-BIB0140|cit140","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/S1470-2045(21)00332-6","article-title":"Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"22","author":"Brose","year":"2021","journal-title":"Lancet Oncology"},{"issue":"24","key":"10.1002\/14651858.CD014872.pub2-BIB0141|cit141","doi-asserted-by":"publisher","first-page":"4203","DOI":"10.1002\/cncr.34493","article-title":"Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: updated results from the phase 3 COSMIC-311 trial","volume":"128","author":"Brose","year":"2022","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0142|cit142","unstructured":"A study of cabozantinib compared with placebo in subjects with radioiodine-refractory differentiated thyroid cancer who have progressed after prior vascular endothelial growth factor receptor (VEGFR) -targeted therapy https:\/\/clinicaltrials.gov\/study\/NCT03690388"},{"issue":"31","key":"10.1002\/14651858.CD014872.pub2-BIB0143|cit143","doi-asserted-by":"publisher","first-page":"4113","DOI":"10.1200\/JCO.2010.31.8162","article-title":"Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer","volume":"29","author":"Brugger","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"10.1002\/14651858.CD014872.pub2-BIB0144|cit144","doi-asserted-by":"publisher","first-page":"9741","DOI":"10.18632\/oncotarget.24188","article-title":"Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers","volume":"9","author":"Cabel","year":"2018","journal-title":"Oncotarget"},{"issue":"1","key":"10.1002\/14651858.CD014872.pub2-BIB0145|cit145","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41392-020-00331-3","article-title":"Combination of anti-PD-1 antibody with P-GEMOX as a potentially effective immunochemotherapy for advanced natural killer\/T cell lymphoma","volume":"5","author":"Cai","year":"2020","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0146|cit146","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ejca.2018.04.004","article-title":"Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer","volume":"97","author":"Cavalieri","year":"2018","journal-title":"European Journal of Cancer"},{"issue":"21","key":"10.1002\/14651858.CD014872.pub2-BIB0147|cit147","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1200\/JCO.19.02630","article-title":"Phase II study of AZD4547 in patients with tumors harboring aberrations in the FGFR pathway: results from the NCI-MATCH trial (EAY131) subprotocol W","volume":"38","author":"Chae","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD014872.pub2-BIB0148|cit148","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1186\/s12885-021-08460-w","article-title":"Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial","volume":"21","author":"Christopoulos","year":"2021","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1002\/14651858.CD014872.pub2-BIB0149|cit149","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/S1470-2045(11)70385-0","article-title":"Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study","volume":"13","author":"Ciuleanu","year":"2012","journal-title":"Lancet Oncology"},{"issue":"154","key":"10.1002\/14651858.CD014872.pub2-BIB0150|cit150","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101377","article-title":"188O EMERALD trial analysis of patient-reported outcomes (PROs) in patients with ER+\/HER2\u2212 advanced or metastatic breast cancer (mBC) comparing oral elacestrant vs standard of care (SoC) endocrine therapy","volume":"8","author":"Cort\u00e9s","year":"2023","journal-title":"European Society for Medical Oncology Open"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0151|cit151","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ejca.2021.07.037","article-title":"Clinical outcomes of patients with metastatic breast cancer enrolled in phase I clinical trials","volume":"157","author":"Criscitiello","year":"2021","journal-title":"European Journal of Cancer"},{"issue":"3","key":"10.1002\/14651858.CD014872.pub2-BIB0152|cit152","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/ejh.13435","article-title":"Clinical benefit of ixazomib plus lenalidomide-dexamethasone in myeloma patients with non-canonical NF-K B pathway activation","volume":"105","author":"Dash","year":"2020","journal-title":"European Journal of Haematology"},{"issue":"10","key":"10.1002\/14651858.CD014872.pub2-BIB0153|cit153","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1080\/10428194.2021.1913144","article-title":"Matching-adjusted indirect comparisons of safety and efficacy of acalabrutinib versus other targeted therapies in patients with treatment-naive chronic lymphocytic leukemia","volume":"62","author":"Davids","year":"2021","journal-title":"Leukemia & Lymphoma"},{"issue":"18","key":"10.1002\/14651858.CD014872.pub2-BIB0154|cit154","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD014872.pub2-BIB0155|cit155","doi-asserted-by":"publisher","first-page":"4054","DOI":"10.21037\/jtd-21-195","article-title":"A phase II study of everolimus in patients with advanced solid malignancies with TSC1, TSC2, NF1, NF2 or STK11 mutations","volume":"13","author":"Devarakonda","year":"2021","journal-title":"Journal of Thoracic Disease"},{"issue":"9","key":"10.1002\/14651858.CD014872.pub2-BIB0156|cit156","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1158\/1535-7163.MCT-12-0290","article-title":"Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials","volume":"11","author":"Dienstmann","year":"2012","journal-title":"Molecular Cancer Therapeutics"},{"issue":"34","key":"10.1002\/14651858.CD014872.pub2-BIB0157|cit157","doi-asserted-by":"publisher","first-page":"4297","DOI":"10.1200\/JCO.2013.50.0322","article-title":"Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer","volume":"31","author":"Domingo","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD014872.pub2-BIB0158|cit158","doi-asserted-by":"publisher","first-page":"255","DOI":"10.2217\/fon-2020-0794","article-title":"A phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma","volume":"17","author":"Dreyling","year":"2021","journal-title":"Future Oncology (London, England)"},{"issue":"3","key":"10.1002\/14651858.CD014872.pub2-BIB0159|cit159","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.18.00345","article-title":"Targeting ERBB2 (HER2) amplification identified by next-generation sequencing in patients with advanced or metastatic solid tumors beyond conventional indications","volume":"21","author":"Dumbrava","year":"2019","journal-title":"Journal of Clinical Oncology Precision Oncology"},{"issue":"10","key":"10.1002\/14651858.CD014872.pub2-BIB0160|cit160","doi-asserted-by":"publisher","first-page":"588","DOI":"10.6061\/clinics\/2017(10)01","article-title":"Next-generation sequencing-based genomic profiling: fostering innovation in cancer care?","volume":"72","author":"Fernandes","year":"2017","journal-title":"Clinics"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0161|cit161","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/s43018-021-00172-1","article-title":"Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors","volume":"2","author":"Fiala","year":"2021","journal-title":"Nature Cancer"},{"issue":"28","key":"10.1002\/14651858.CD014872.pub2-BIB0162|cit162","doi-asserted-by":"publisher","first-page":"4339","DOI":"10.1200\/JCO.2010.28.9678","article-title":"Phase IIB trial of oral midostaurin (PKC412), the fms-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3","volume":"28","author":"Fischer","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"33","key":"10.1002\/14651858.CD014872.pub2-BIB0163|cit163","doi-asserted-by":"publisher","first-page":"3883","DOI":"10.1200\/JCO.19.03010","article-title":"Molecular landscape and actionable alterations in a genomically guided cancer clinical trial: National Cancer Institute molecular analysis for therapy choice (NCI-MATCH)","volume":"38","author":"Flaherty","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"10.1002\/14651858.CD014872.pub2-BIB0164|cit164","doi-asserted-by":"publisher","first-page":"4540","DOI":"10.1111\/cas.14671","article-title":"Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: an open-label phase II trial","volume":"111","author":"Fukano","year":"2020","journal-title":"Cancer Science"},{"issue":"1","key":"10.1002\/14651858.CD014872.pub2-BIB0165|cit165","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cct.2014.06.016","article-title":"Comparative effectiveness of next generation genomic sequencing for disease diagnosis: design of a randomized controlled trial in patients with colorectal cancer\/polyposis syndromes","volume":"39","author":"Gallego","year":"2014","journal-title":"Contemporary Clinical Trials"},{"issue":"9","key":"10.1002\/14651858.CD014872.pub2-BIB0166|cit166","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1038\/s41416-021-01502-x","article-title":"Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study","volume":"125","author":"Gambardella","year":"2021","journal-title":"British Journal of Cancer"},{"issue":"13","key":"10.1002\/14651858.CD014872.pub2-BIB0167|cit167","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1200\/JCO.2016.70.9352","article-title":"Targeting RET in patients with RET-rearranged lung cancers: results from the global, multicenter RET registry","volume":"35","author":"Gautschi","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD014872.pub2-BIB0168|cit168","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/bjh.17519","article-title":"Application of the EuroClonality next-generation sequencing-based marker screening approach to detect immunoglobulin heavy chain rearrangements in mantle cell lymphoma patients: first data from the Fondazione Italiana Linfomi MCL0208 trial","volume":"194","author":"Genuardi","year":"2021","journal-title":"British Journal of Haematology"},{"issue":"48","key":"10.1002\/14651858.CD014872.pub2-BIB0169|cit169","doi-asserted-by":"publisher","first-page":"79428","DOI":"10.18632\/oncotarget.12714","article-title":"Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study","volume":"7","author":"Gon\u00e7alves","year":"2016","journal-title":"Oncotarget"},{"issue":"20","key":"10.1002\/14651858.CD014872.pub2-BIB0170|cit170","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.2217\/fon-2017-0582","article-title":"ASP2215 in the treatment of relapsed\/refractory acute myeloid leukemia with FLT3 mutation: background and design of the ADMIRAL trial","volume":"14","author":"Gorcea","year":"2018","journal-title":"Future Oncology (London, England)"},{"issue":"13","key":"10.1002\/14651858.CD014872.pub2-BIB0171|cit171","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S1470-2045(15)00087-X","article-title":"Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-V): results of a phase 3, open-label, randomised trial","volume":"16","author":"Grob","year":"2015","journal-title":"Lancet Oncology"},{"issue":"5","key":"10.1002\/14651858.CD014872.pub2-BIB0172|cit172","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1093\/annonc\/mdu054","article-title":"DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma","volume":"25","author":"Gupta","year":"2014","journal-title":"Annals of Oncology"},{"issue":"7","key":"10.1002\/14651858.CD014872.pub2-BIB0173|cit173","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1158\/1078-0432.CCR-17-2297","article-title":"Genomic correlates of response to everolimus in aggressive radioiodine-refractory thyroid cancer: a phase II study","volume":"24","author":"Hanna","year":"2018","journal-title":"Clinical Cancer Research"},{"issue":"20","key":"10.1002\/14651858.CD014872.pub2-BIB0174|cit174","doi-asserted-by":"publisher","first-page":"6101","DOI":"10.1158\/1078-0432.CCR-17-0381","article-title":"Molecular screening for cancer treatment optimization (MOSCATO-01) in pediatric patients: a single-institutional prospective molecular stratification trial","volume":"23","author":"Harttrampf","year":"2017","journal-title":"Clinical Cancer Research"},{"issue":"7","key":"10.1002\/14651858.CD014872.pub2-BIB0175|cit175","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1158\/1078-0432.CCR-11-0563","article-title":"Phase II efficacy and pharmacogenomic study of selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements","volume":"18","author":"Hayes","year":"2012","journal-title":"Clinical Cancer Research"},{"issue":"9","key":"10.1002\/14651858.CD014872.pub2-BIB0176|cit176","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1002\/ijc.31091","article-title":"Value of a molecular screening program to support clinical trial enrollment in Asian cancer patients: the Integrated Molecular Analysis of Cancer (IMAC) study","volume":"142","author":"Heong","year":"2018","journal-title":"International Journal of Cancer"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0177|cit177","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1200\/PO.20.00248","article-title":"CATCH: a prospective precision oncology trial in metastatic breast cancer","volume":"5","author":"Hlevnjak","year":"2021","journal-title":"Journal of Clinical Oncology Precision Oncology"},{"issue":"5","key":"10.1002\/14651858.CD014872.pub2-BIB0178|cit178","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1200\/JCO.2014.60.1971","article-title":"Correlative analysis of genetic alterations and everolimus benefit in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from BOLERO-2","volume":"34","author":"Hortobagyi","year":"2016","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD014872.pub2-BIB0179|cit179","doi-asserted-by":"publisher","first-page":"438","DOI":"10.3324\/haematol.2017.181297","article-title":"Benefits and pitfalls of pegylated interferon-alpha2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of myeloproliferative neoplasms (FIM) study","volume":"103","author":"Ianotto","year":"2018","journal-title":"Haematologica"},{"issue":"2","key":"10.1002\/14651858.CD014872.pub2-BIB0180|cit180","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41422-020-0375-9","article-title":"Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial","volume":"31","author":"Jiang","year":"2021","journal-title":"Cell Research"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0181|cit181","doi-asserted-by":"publisher","first-page":"860711","DOI":"10.3389\/fonc.2023.860711","article-title":"Targeted therapy for intractable cancer on the basis of molecular profiles: an open-label, phase II basket trial (Long March Pathway)","volume":"13","author":"Jiao","year":"2023","journal-title":"Frontiers in Oncology"},{"issue":"8","key":"10.1002\/14651858.CD014872.pub2-BIB0182|cit182","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1158\/1078-0432.CCR-19-3443","article-title":"Trametinib activity in patients with solid tumors and lymphomas harboring braf non-V600 mutations or fusions: results from NCI-MATCH (EAY131)","volume":"26","author":"Johnson","year":"2020","journal-title":"Clinical Cancer Research"},{"issue":"2","key":"10.1002\/14651858.CD014872.pub2-BIB0183|cit183","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.clcc.2014.12.003","article-title":"FOLFOX4 plus cetuximab for patients with previously untreated metastatic colorectal cancer according to tumor RAS and BRAF mutation status: updated analysis of the CECOG\/CORE 1.2.002 study","volume":"14","author":"Kaczirek","year":"2015","journal-title":"Clinical Colorectal Cancer"},{"issue":"12","key":"10.1002\/14651858.CD014872.pub2-BIB0184|cit184","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1634\/theoncologist.2020-0681","article-title":"Phase II trial of palbociclib in patients with advanced esophageal or gastric cancer","volume":"25","author":"Karasic","year":"2020","journal-title":"Oncologist"},{"issue":"10","key":"10.1002\/14651858.CD014872.pub2-BIB0185|cit185","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1089\/thy.2013.0057","article-title":"Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAFV600E mutation","volume":"23","author":"Kim","year":"2013","journal-title":"Thyroid"},{"issue":"32","key":"10.1002\/14651858.CD014872.pub2-BIB0186|cit186","doi-asserted-by":"publisher","first-page":"33358","DOI":"10.18632\/oncotarget.5188","article-title":"The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis","volume":"6","author":"Kim","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"10.1002\/14651858.CD014872.pub2-BIB0187|cit187","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.16.00059","article-title":"Prospective feasibility study for using cell-free circulating tumor DNA-guided therapy in refractory metastatic solid cancers: an interim analysis","volume":"1","author":"Kim","year":"2017","journal-title":"Journal of Clinical Oncology Precision Oncology"},{"issue":"10","key":"10.1002\/14651858.CD014872.pub2-BIB0188|cit188","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1634\/theoncologist.2017-0020","article-title":"Clinical application of targeted deep sequencing in solid-cancer patients and utility for biomarker-selected clinical trials","volume":"22","author":"Kim","year":"2017","journal-title":"Oncologist"},{"issue":"6","key":"10.1002\/14651858.CD014872.pub2-BIB0189|cit189","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1002\/ijc.32188","article-title":"Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positive breast cancer patients","volume":"145","author":"Kim","year":"2019","journal-title":"International Journal of Cancer"},{"issue":"36","key":"10.1002\/14651858.CD014872.pub2-BIB0190|cit190","doi-asserted-by":"publisher","first-page":"5013","DOI":"10.2217\/fon-2021-0899","article-title":"Olaparib with or without bevacizumab or bevacizumab and 5-fluorouracil in advanced colorectal cancer: phase III LYNK-003","volume":"17","author":"Kim","year":"2021","journal-title":"Future Oncology (London, England)"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0191|cit191","doi-asserted-by":"publisher","first-page":"114036","DOI":"10.1016\/j.ejca.2024.114036","article-title":"Olaparib with or without bevacizumab versus bevacizumab plus a fluoropyrimidine as maintenance therapy in advanced colorectal cancer: the randomized phase 3 LYNK-003 study","volume":"205","author":"Takashima","year":"2024","journal-title":"European Journal of Cancer"},{"issue":"1","key":"10.1002\/14651858.CD014872.pub2-BIB0192|cit192","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1158\/1078-0432.CCR-15-0979","article-title":"A multicenter, open-label phase II clinical trial of combined MEK plus EGFR inhibition for chemotherapy-refractory advanced pancreatic adenocarcinoma","volume":"22","author":"Ko","year":"2016","journal-title":"Clinical Cancer Research"},{"issue":"19","key":"10.1002\/14651858.CD014872.pub2-BIB0193|cit193","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1001\/jama.2014.3741","article-title":"Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs","volume":"311","author":"Kris","year":"2014","journal-title":"JAMA"},{"issue":"4","key":"10.1002\/14651858.CD014872.pub2-BIB0194|cit194","doi-asserted-by":"publisher","first-page":"538","DOI":"10.3324\/haematol.2011.053348","article-title":"Decrease in JAK2V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera","volume":"97","author":"Kuriakose","year":"2012","journal-title":"Haematologica"},{"issue":"12","key":"10.1002\/14651858.CD014872.pub2-BIB0195|cit195","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1136\/jclinpath-2017-204621","article-title":"Molecular profiling and targeted inhibitor therapy in atypical chronic myeloid leukaemia in blast crisis","volume":"70","author":"Langabeer","year":"2017","journal-title":"Journal of Clinical Pathology"},{"issue":"9","key":"10.1002\/14651858.CD014872.pub2-BIB0196|cit196","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1038\/s41375-021-01179-4","article-title":"Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603\/RATIFY trial","volume":"35","author":"Larson","year":"2021","journal-title":"Leukemia"},{"issue":"3","key":"10.1002\/14651858.CD014872.pub2-BIB0197|cit197","doi-asserted-by":"publisher","first-page":"89473","DOI":"10.1172\/jci.insight.89473","article-title":"Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes","volume":"2","author":"Lee","year":"2017","journal-title":"Journal of Clinical Investigation Insight"},{"issue":"1","key":"10.1002\/14651858.CD014872.pub2-BIB0198|cit198","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.clcc.2020.09.003","article-title":"Association of consensus molecular subtypes and molecular markers with clinical outcomes in patients with metastatic colorectal cancer: biomarker analyses from LUME-Colon 1","volume":"20","author":"Lenz","year":"2021","journal-title":"Clinical Colorectal Cancer"},{"issue":"17","key":"10.1002\/14651858.CD014872.pub2-BIB0199|cit199","doi-asserted-by":"publisher","first-page":"5212","DOI":"10.1158\/1078-0432.CCR-18-4173","article-title":"Safety, efficacy, and biomarker analysis of pyrotinib in combination with capecitabine in HER2-positive metastatic breast cancer patients: a phase I clinical trial","volume":"25","author":"Li","year":"2019","journal-title":"Clinical Cancer Research"},{"issue":"4","key":"10.1002\/14651858.CD014872.pub2-BIB0200|cit200","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD014872.pub2-BIB0201|cit201","doi-asserted-by":"publisher","first-page":"343","DOI":"10.21147\/j.issn.1000-9604.2022.04.03","article-title":"Clinical value of next-generation sequencing in guiding decisions regarding endocrine therapy for advanced HR-positive\/HER-2-negative breast cancer","volume":"34","author":"Lyu","year":"2022","journal-title":"Chinese Journal of Cancer Research"},{"issue":"27","key":"10.1002\/14651858.CD014872.pub2-BIB0202|cit202","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1200\/JCO.2016.69.6179","article-title":"Phase I study and biomarker analysis of pyrotinib, a novel irreversible pan-ErbB receptor tyrosine kinase inhibitor, in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer","volume":"35","author":"Ma","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"22","key":"10.1002\/14651858.CD014872.pub2-BIB0203|cit203","doi-asserted-by":"publisher","first-page":"6823","DOI":"10.1158\/1078-0432.CCR-17-1260","article-title":"A phase II trial of neoadjuvant MK-2206, an AKT inhibitor, with anastrozole in clinical stage II or III PIK3CA-mutant ER-positive and HER2-negative breast cancer","volume":"23","author":"Ma","year":"2017","journal-title":"Clinical Cancer Research"},{"issue":"25","key":"10.1002\/14651858.CD014872.pub2-BIB0204|cit204","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0205|cit205","doi-asserted-by":"publisher","first-page":"175883592199650","DOI":"10.1177\/1758835921996509","article-title":"Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer","volume":"13","author":"Magios","year":"2021","journal-title":"Therapeutic Advances in Medical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD014872.pub2-BIB0206|cit206","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1158\/2159-8290.CD-16-1396","article-title":"High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial","volume":"7","author":"Massard","year":"2017","journal-title":"Cancer Discovery"},{"issue":"9","key":"10.1002\/14651858.CD014872.pub2-BIB0207|cit207","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1038\/bjc.2014.182","article-title":"A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): a model for randomised controlled trials in the era of personalised medicine?","volume":"110","author":"Maughan","year":"2014","journal-title":"British Journal of Cancer"},{"issue":"1","key":"10.1002\/14651858.CD014872.pub2-BIB0208|cit208","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/1078-0432.CCR-16-0134","article-title":"A phase Ib study of alpelisib (BYL719), a PI3Kalpha-specific inhibitor, with letrozole in ER+\/HER2- metastatic breast cancer","volume":"23","author":"Mayer","year":"2017","journal-title":"Clinical Cancer Research"},{"issue":"12","key":"10.1002\/14651858.CD014872.pub2-BIB0209|cit209","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1093\/annonc\/mdv394","article-title":"The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancer","volume":"26","author":"Middleton","year":"2015","journal-title":"Annals of Oncology"},{"issue":"7818","key":"10.1002\/14651858.CD014872.pub2-BIB0210|cit210","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41586-020-2656-3","article-title":"The National Lung Matrix Trial of personalized therapy in lung cancer","volume":"583","author":"Middleton","year":"2020","journal-title":"Nature"},{"issue":"1","key":"10.1002\/14651858.CD014872.pub2-BIB0211|cit211","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD014872.pub2-BIB0212|cit212","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/hed.26026","article-title":"Next-generation sequencing in salivary gland carcinoma: targetable alterations lead to a therapeutic advantage - multicenter experience","volume":"42","author":"Moore","year":"2020","journal-title":"Head & Neck"},{"issue":"25","key":"10.1002\/14651858.CD014872.pub2-BIB0213|cit213","doi-asserted-by":"publisher","first-page":"26388","DOI":"10.1097\/MD.0000000000026388","article-title":"Next-generation sequencing in thyroid cancers: do targetable alterations lead to a therapeutic advantage?: a multicenter experience","volume":"100","author":"Moore","year":"2021","journal-title":"Medicine"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0214|cit214","doi-asserted-by":"publisher","first-page":"106522","DOI":"10.1016\/j.leukres.2021.106522","article-title":"Targeted therapy for treatment of patients with classical hairy cell leukemia","volume":"102","author":"Moore","year":"2021","journal-title":"Leukemia Research"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0215|cit215","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.18.00263","article-title":"Concordance of genomic variants in matched primary breast cancer, metastatic tumor, and circulating tumor DNA: the MIRROR study","volume":"3","author":"Moreno","year":"2019","journal-title":"Journal of Clinical Oncology Precision Oncology"},{"issue":"11","key":"10.1002\/14651858.CD014872.pub2-BIB0216|cit216","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","article-title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial","volume":"21","author":"Morschhauser","year":"2020","journal-title":"Lancet Oncology"},{"issue":"1","key":"10.1002\/14651858.CD014872.pub2-BIB0217|cit217","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ccell.2020.12.021","article-title":"The NCI-MATCH: a national, collaborative precision oncology trial for diverse tumor histologies","volume":"39","author":"Murciano-Goroff","year":"2021","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1002\/14651858.CD014872.pub2-BIB0218|cit218","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ygyno.2016.02.025","article-title":"Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): an NRG Oncology\/Gynecologic Oncology Group study","volume":"141","author":"Myers","year":"2016","journal-title":"Gynecologic Oncology"},{"issue":"19","key":"10.1002\/14651858.CD014872.pub2-BIB0219|cit219","doi-asserted-by":"publisher","first-page":"5258","DOI":"10.1158\/1078-0432.CCR-21-0273","article-title":"RELAY subgroup analyses by EGFR Ex19del and Ex21L858R mutations for ramucirumab plus erlotinib in metastatic non-small cell lung cancer","volume":"27","author":"Nakagawa","year":"2021","journal-title":"Clinical Cancer Research"},{"issue":"13","key":"10.1002\/14651858.CD014872.pub2-BIB0220|cit220","doi-asserted-by":"publisher","first-page":"3362","DOI":"10.3390\/cancers13133362","article-title":"TP53 mutation as a prognostic and predictive marker in sarcoma: pooled analysis of MOSCATO and ProfiLER precision medicine trials","volume":"13","author":"Nassif","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1002\/14651858.CD014872.pub2-BIB0221|cit221","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/s41523-024-00684-w","article-title":"A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive\/HER2-negative advanced breast cancer","volume":"10","author":"Noguchi","year":"2024","journal-title":"Nature Partner Journals Breast Cancer"},{"issue":"8","key":"10.1002\/14651858.CD014872.pub2-BIB0222|cit222","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1093\/annonc\/mdv176","article-title":"Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial","volume":"26","author":"Normanno","year":"2015","journal-title":"Annals of Oncology"},{"issue":"8","key":"10.1002\/14651858.CD014872.pub2-BIB0223|cit223","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1038\/s41416-018-0290-8","article-title":"Target-based therapeutic matching of phase I trials in patients with metastatic breast cancer in a tertiary referral centre","volume":"119","author":"O'Carrigan","year":"2018","journal-title":"British Journal of Cancer"},{"issue":"6","key":"10.1002\/14651858.CD014872.pub2-BIB0224|cit224","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1634\/theoncologist.2017-0642","article-title":"FDA approval summary: dabrafenib and trametinib for the treatment of metastatic non-small cell lung cancers harboring BRAF V600E mutations","volume":"23","author":"Odogwu","year":"2018","journal-title":"Oncologist"},{"issue":"12","key":"10.1002\/14651858.CD014872.pub2-BIB0225|cit225","doi-asserted-by":"publisher","first-page":"e15588","DOI":"10.1371\/journal.pone.0015588","article-title":"A phase II trial of sorafenib in metastatic melanoma with tissue correlates","volume":"5","author":"Ott","year":"2010","journal-title":"PloS One"},{"issue":"1","key":"10.1002\/14651858.CD014872.pub2-BIB0226|cit226","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jitc-2020-000587","article-title":"Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer","volume":"8","author":"Overman","year":"2020","journal-title":"Journal for Immunotherapy of Cancer"},{"issue":"30","key":"10.1002\/14651858.CD014872.pub2-BIB0227|cit227","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1200\/JCO.2015.66.0084","article-title":"The BATTLE-2 study: a biomarker-integrated targeted therapy study in previously treated patients with advanced non-small-cell lung cancer","volume":"34","author":"Papadimitrakopoulou","year":"2016","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0228|cit228","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.lungcan.2021.03.012","article-title":"Phase I results of S49076 plus gefitinib in patients with EGFR TKI-resistant non-small cell lung cancer harbouring MET\/AXL dysregulation","volume":"155","author":"Park","year":"2021","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"issue":"1","key":"10.1002\/14651858.CD014872.pub2-BIB0229|cit229","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s10549-017-4580-2","article-title":"Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer","volume":"168","author":"Pezo","year":"2018","journal-title":"Breast Cancer Research and Treatment"},{"issue":"14","key":"10.1002\/14651858.CD014872.pub2-BIB0230|cit230","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.2217\/fon-2017-0592","article-title":"Phase III study with FOLFIRI + cetuximab versus FOLFIRI + cetuximab followed by cetuximab alone in RAS and BRAF WT mCRC","volume":"14","author":"Pinto","year":"2018","journal-title":"Future Oncology (London, England)"},{"issue":"5","key":"10.1002\/14651858.CD014872.pub2-BIB0231|cit231","doi-asserted-by":"publisher","first-page":"e0155959","DOI":"10.1371\/journal.pone.0155959","article-title":"Interferon-alpha revisited: individualized treatment management eased the selective pressure of tyrosine kinase inhibitors on BCR-ABL1 mutations resulting in a molecular response in high-risk CML patients","volume":"11","author":"Polivkova","year":"2016","journal-title":"PloS One"},{"issue":"6","key":"10.1002\/14651858.CD014872.pub2-BIB0232|cit232","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1038\/bjc.2015.37","article-title":"Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer","volume":"112","author":"Price","year":"2015","journal-title":"British Journal of Cancer"},{"issue":"1","key":"10.1002\/14651858.CD014872.pub2-BIB0233|cit233","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1182\/blood-2018-07-865428","article-title":"Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016","volume":"133","author":"Qu","year":"2019","journal-title":"Blood"},{"issue":"7","key":"10.1002\/14651858.CD014872.pub2-BIB0234|cit234","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1634\/theoncologist.2017-0552","article-title":"Cabozantinib in patients with advanced merkel cell carcinoma","volume":"23","author":"Rabinowits","year":"2018","journal-title":"Oncologist"},{"issue":"18","key":"10.1002\/14651858.CD014872.pub2-BIB0235|cit235","doi-asserted-by":"publisher","first-page":"3298","DOI":"10.1002\/cncr.29480","article-title":"Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer","volume":"121","author":"Reckamp","year":"2015","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0236|cit236","doi-asserted-by":"publisher","first-page":"102624","DOI":"10.1016\/j.ebiom.2019.102624","article-title":"Implementation and use of whole exome sequencing for metastatic solid cancer","volume":"51","author":"R\u00e9da","year":"2020","journal-title":"EBioMedicine"},{"issue":"12","key":"10.1002\/14651858.CD014872.pub2-BIB0237|cit237","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1016\/S1470-2045(20)30475-7","article-title":"Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol","volume":"21","author":"Redman","year":"2020","journal-title":"Lancet Oncology"},{"issue":"7","key":"10.1002\/14651858.CD014872.pub2-BIB0238|cit238","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1080\/0284186X.2020.1742377","article-title":"Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer - the MetAction study","volume":"59","author":"Ree","year":"2020","journal-title":"Acta Oncologica"},{"issue":"1","key":"10.1002\/14651858.CD014872.pub2-BIB0239|cit239","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s40425-018-0436-5","article-title":"STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial","volume":"6","author":"Reilley","year":"2018","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0240|cit240","doi-asserted-by":"publisher","first-page":"114103","DOI":"10.1016\/j.ejca.2024.114103","article-title":"Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: results from the randomized phase II RE-AKT trial","volume":"205","author":"Rescigno","year":"2024","journal-title":"European Journal of Cancer"},{"issue":"5","key":"10.1002\/14651858.CD014872.pub2-BIB0241|cit241","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/s41591-019-0424-4","article-title":"Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial","volume":"25","author":"Rodon","year":"2019","journal-title":"Nature Medicine"},{"issue":"29","key":"10.1002\/14651858.CD014872.pub2-BIB0242|cit242","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.18632\/oncotarget.27656","article-title":"Genomic markers of midostaurin drug sensitivity in FLT3 mutated and FLT3 wild-type acute myeloid leukemia patients","volume":"11","author":"Rosenberg","year":"2020","journal-title":"Oncotarget"},{"issue":"5","key":"10.1002\/14651858.CD014872.pub2-BIB0243|cit243","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/s41591-019-0380-z","article-title":"Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study","volume":"25","author":"Rothwell","year":"2019","journal-title":"Nature Medicine"},{"issue":"6","key":"10.1002\/14651858.CD014872.pub2-BIB0244|cit244","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1093\/jnci\/djy156","article-title":"A prospective study of circulating tumor DNA to guide matched targeted therapy in cancers","volume":"111","author":"Sabari","year":"2019","journal-title":"Journal of the National Cancer Institute"},{"issue":"1","key":"10.1002\/14651858.CD014872.pub2-BIB0245|cit245","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.cllc.2015.08.001","article-title":"EGFR and KRAS mutations in ALK-positive lung adenocarcinomas: biological and clinical effect","volume":"17","author":"Sahnane","year":"2016","journal-title":"Clinical Lung Cancer"},{"issue":"8","key":"10.1002\/14651858.CD014872.pub2-BIB0246|cit246","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.3390\/cancers12082242","article-title":"High throughput molecular characterization of normal karyotype acute myeloid leukemia in the context of the prospective trial 02\/06 of the Northern Italy Leukemia Group (NILG)","volume":"12","author":"Salmoiraghi","year":"2020","journal-title":"Cancers"},{"issue":"1","key":"10.1002\/14651858.CD014872.pub2-BIB0247|cit247","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41416-021-01399-6","article-title":"Circulating tumour cells and cell-free DNA as a prognostic factor in metastatic colorectal cancer: the OMITERC prospective study","volume":"125","author":"Salvianti","year":"2021","journal-title":"British Journal of Cancer"},{"issue":"78","key":"10.1002\/14651858.CD014872.pub2-BIB0248|cit248","doi-asserted-by":"publisher","first-page":"34794","DOI":"10.18632\/oncotarget.26198","article-title":"Multi-omic based molecular profiling of advanced cancer identifies treatable targets and improves survival in individual patients","volume":"9","author":"Samsen","year":"2018","journal-title":"Oncotarget"},{"issue":"12","key":"10.1002\/14651858.CD014872.pub2-BIB0249|cit249","doi-asserted-by":"publisher","first-page":"10577","DOI":"10.18632\/oncotarget.3387","article-title":"ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability","volume":"6","author":"Scheffler","year":"2015","journal-title":"Oncotarget"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0250|cit250","unstructured":"A multicenter, randomized, double-blind, placebo-controlled, trial of lenvatinib (E7080) in 131I-refractory differentiated thyroid cancer (DTC) (SELECT) https:\/\/clinicaltrials.gov\/study\/NCT01321554"},{"issue":"7","key":"10.1002\/14651858.CD014872.pub2-BIB0251|cit251","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD014872.pub2-BIB0252|cit252","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1158\/1535-7163.MCT-15-0795","article-title":"Precision oncology: the UC San Diego Moores Cancer center PREDICT experience","volume":"15","author":"Schwaederle","year":"2016","journal-title":"Molecular Cancer Therapeutics"},{"issue":"2","key":"10.1002\/14651858.CD014872.pub2-BIB0253|cit253","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.tranon.2018.10.011","article-title":"A pilot prospective study of refractory solid tumor patients for NGS-based targeted anticancer therapy","volume":"12","author":"Seol","year":"2019","journal-title":"Translational Oncology"},{"issue":"8","key":"10.1002\/14651858.CD014872.pub2-BIB0254|cit254","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/S1470-2045(13)70163-3","article-title":"Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial","volume":"14","author":"Seymour","year":"2013","journal-title":"Lancet Oncology"},{"issue":"16","key":"10.1002\/14651858.CD014872.pub2-BIB0255|cit255","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1200\/JCO.18.02236","article-title":"ALK resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer","volume":"37","author":"Shaw","year":"2019","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD014872.pub2-BIB0256|cit256","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/cncr.33293","article-title":"Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations","volume":"127","author":"Shoukier","year":"2021","journal-title":"Cancer"},{"issue":"36","key":"10.1002\/14651858.CD014872.pub2-BIB0257|cit257","doi-asserted-by":"publisher","first-page":"4027","DOI":"10.1200\/JCO.2017.73.9250","article-title":"Gefitinib plus chemotherapy versus chemotherapy in epidermal growth factor receptor mutation-positive non-small-cell lung cancer resistant to first-line gefitinib (IMPRESS): overall survival and biomarker analyses","volume":"35","author":"Mok","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1002\/14651858.CD014872.pub2-BIB0258|cit258","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/S1470-2045(15)00121-7","article-title":"Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial","volume":"16","author":"Soria","year":"2015","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0259|cit259","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.ejca.2020.07.003","article-title":"Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: next-generation sequencing results of the FIRE-3 trial","volume":"137","author":"Stahler","year":"2020","journal-title":"European Journal of Cancer"},{"issue":"1","key":"10.1002\/14651858.CD014872.pub2-BIB0260|cit260","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jtho.2020.09.018","article-title":"Preliminary clinical and molecular analysis results from a single-arm phase 2 trial of brigatinib in patients with disease progression after next-generation ALK tyrosine kinase inhibitors in advanced ALK+ NSCLC","volume":"16","author":"Stinchcombe","year":"2021","journal-title":"Journal of Thoracic Oncology"},{"issue":"1","key":"10.1002\/14651858.CD014872.pub2-BIB0261|cit261","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13073-016-0364-2","article-title":"Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT\/COMPACT trial","volume":"8","author":"Stockley","year":"2016","journal-title":"Genome Medicine"},{"issue":"5","key":"10.1002\/14651858.CD014872.pub2-BIB0262|cit262","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD014872.pub2-BIB0263|cit263","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial","volume":"18","author":"Swisher","year":"2017","journal-title":"Lancet Oncology"},{"issue":"7","key":"10.1002\/14651858.CD014872.pub2-BIB0264|cit264","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1200\/JCO.2009.22.6043","article-title":"Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study","volume":"28","author":"Tabernero","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"10.1002\/14651858.CD014872.pub2-BIB0265|cit265","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1093\/annonc\/mdv475","article-title":"Clinical application of amplicon-based next-generation sequencing to therapeutic decision making in lung cancer","volume":"26","author":"Takeda","year":"2015","journal-title":"Annals of Oncology"},{"issue":"8","key":"10.1002\/14651858.CD014872.pub2-BIB0266|cit266","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1002\/cncr.33364","article-title":"Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers","volume":"127","author":"Tan","year":"2021","journal-title":"Cancer"},{"issue":"1","key":"10.1002\/14651858.CD014872.pub2-BIB0267|cit267","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12943-016-0553-z","article-title":"Comprehensive screening of target molecules by next-generation sequencing in patients with malignant solid tumors: guiding entry into phase I clinical trials","volume":"15","author":"Tanabe","year":"2016","journal-title":"Molecular Cancer"},{"issue":"19","key":"10.1002\/14651858.CD014872.pub2-BIB0268|cit268","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1056\/NEJMoa2031298","article-title":"Vemurafenib plus rituximab in refractory or relapsed hairy-cell leukemia","volume":"384","author":"Tiacci","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"15","key":"10.1002\/14651858.CD014872.pub2-BIB0269|cit269","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1200\/JCO.2011.38.0915","article-title":"Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study","volume":"30","author":"Tveit","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD014872.pub2-BIB0270|cit270","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1002\/ijc.33303","article-title":"A higher ctDNA fraction decreases survival in regorafenib-treated metastatic colorectal cancer patients. Results from the regorafenib's liquid biopsy translational biomarker phase II pilot study","volume":"148","author":"Unseld","year":"2021","journal-title":"International Journal of Cancer"},{"issue":"1","key":"10.1002\/14651858.CD014872.pub2-BIB0271|cit271","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ygyno.2022.01.034","article-title":"Randomized CLIO\/BGOG-ov10 trial of olaparib monotherapy versus physician's choice chemotherapy in relapsed ovarian cancer","volume":"165","author":"Vanderstichele","year":"2022","journal-title":"Gynecologic Oncology"},{"issue":"8","key":"10.1002\/14651858.CD014872.pub2-BIB0272|cit272","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.urolonc.2017.03.009","article-title":"Description of the EuroTARGET cohort: a European collaborative project on targeted therapy in renal cell cancer-genetic- and tumor-related biomarkers for response and toxicity","volume":"35","author":"Van der Zanden","year":"2017","journal-title":"Urologic Oncology"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0273|cit273","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ejca.2019.06.017","article-title":"Actionable molecular alterations in advanced gynaecologic malignancies: updated results from the ProfiLER programme","volume":"118","author":"Varnier","year":"2019","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0274|cit274","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ejca.2017.10.013","article-title":"Precision medicine for patients with advanced biliary tract cancers: an effective strategy within the prospective MOSCATO-01 trial","volume":"87","author":"Verlingue","year":"2017","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0275|cit275","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2017.12.020","article-title":"Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: entering the back door","volume":"92","author":"Verlingue","year":"2018","journal-title":"European Journal of Cancer"},{"issue":"32","key":"10.1002\/14651858.CD014872.pub2-BIB0276|cit276","doi-asserted-by":"publisher","first-page":"3846","DOI":"10.1200\/JCO.2016.67.9084","article-title":"Phase II trial and correlative genomic analysis of everolimus plus bevacizumab in advanced non-clear cell renal cell carcinoma","volume":"34","author":"Voss","year":"2016","journal-title":"Journal of Clinical Oncology"},{"issue":"33","key":"10.1002\/14651858.CD014872.pub2-BIB0277|cit277","doi-asserted-by":"publisher","first-page":"3911","DOI":"10.1200\/JCO.2014.59.1503","article-title":"Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma","volume":"33","author":"Walker","year":"2015","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"10.1002\/14651858.CD014872.pub2-BIB0278|cit278","doi-asserted-by":"publisher","first-page":"3437","DOI":"10.1002\/cam4.956","article-title":"Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience","volume":"5","author":"Wang","year":"2016","journal-title":"Cancer Medicine"},{"issue":"9","key":"10.1002\/14651858.CD014872.pub2-BIB0279|cit279","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S2213-2600(18)30264-9","article-title":"Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial","volume":"6","author":"Wang","year":"2018","journal-title":"Lancet Respiratory Medicine"},{"issue":"2","key":"10.1002\/14651858.CD014872.pub2-BIB0280|cit280","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1634\/theoncologist.2018-0120","article-title":"Erlotinib as neoadjuvant therapy in stage IIIA (N2) EGFR mutation-positive non-small cell lung cancer: a prospective, single-arm, phase II study","volume":"24","author":"Xiong","year":"2019","journal-title":"Oncologist"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0281|cit281","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41523-020-00201-9","article-title":"Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer","volume":"6","author":"Yi","year":"2020","journal-title":"Nature Partner Journals Breast Cancer"},{"issue":"11","key":"10.1002\/14651858.CD014872.pub2-BIB0282|cit282","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1158\/1078-0432.CCR-13-3140","article-title":"KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance)","volume":"20","author":"Yoon","year":"2014","journal-title":"Clinical Cancer Research"},{"issue":"4","key":"10.1002\/14651858.CD014872.pub2-BIB0283|cit283","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s00262-020-02745-y","article-title":"Next-generation sequencing-guided molecular-targeted therapy and immunotherapy for biliary tract cancers","volume":"70","author":"Zhang","year":"2021","journal-title":"Cancer Immunology, Immunotherapy"},{"issue":"1","key":"10.1002\/14651858.CD014872.pub2-BIB0284|cit284","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s12916-021-02089-z","article-title":"Utility of comprehensive genomic profiling in directing treatment and improving patient outcomes in advanced non-small cell lung cancer","volume":"19","author":"Zhao","year":"2021","journal-title":"BMC Medicine"},{"issue":"1","key":"10.1002\/14651858.CD014872.pub2-BIB0285|cit285","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.cllc.2017.06.008","article-title":"Prospective clinical integration of an amplicon-based next-generation sequencing method to select advanced non-small-cell lung cancer patients for genotype-tailored treatments","volume":"19","author":"Zugazagoitia","year":"2018","journal-title":"Clinical Lung Cancer"},{"issue":"16 Suppl","key":"10.1002\/14651858.CD014872.pub2-BIB0286|cit286","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.1200\/JCO.2024.42.16_suppl.3157","article-title":"Genomics to select treatment for patients (pts) with metastatic cancer: final analysis of Molecular Tumor Board (MTB) evaluations in the ROME trial","volume":"42","author":"Botticelli","year":"2024","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0287|cit287","unstructured":"The Rome trial from histology to target: the road to personalize target therapy and immunotherapy (ROME) https:\/\/clinicaltrials.gov\/study\/NCT04591431"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0288|cit288","doi-asserted-by":"publisher","first-page":"v896","DOI":"10.1093\/annonc\/mdz394.055","article-title":"BAROCCO: a randomized phase II study of weekly paclitaxel vs cediranib-olaparib combination given with continuous or intermittent schedule in patients with recurrent platinum resistant ovarian cancer (PROC)","volume":"30","author":"Colombo","year":"2019","journal-title":"Annals of Oncology"},{"issue":"3","key":"10.1002\/14651858.CD014872.pub2-BIB0289|cit289","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.ygyno.2022.01.015","article-title":"Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer","volume":"164","author":"Colombo","year":"2022","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0290|cit290","unstructured":"Best approach in recurrent-ovarian-cancer-with cediranib-olaparib (BAROCCO) https:\/\/clinicaltrials.gov\/study\/NCT03314740"},{"issue":"23","key":"10.1002\/14651858.CD014872.pub2-BIB0291|cit291","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1056\/NEJMoa2308795","article-title":"Sotorasib plus panitumumab in refractory colorectal cancer with mutated KRAS G12C","volume":"389","author":"Fakih","year":"2023","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0292|cit292","unstructured":"Sotorasib and panitumumab versus investigator's choice for participants with kirsten rat sarcoma (KRAS) p.g12c mutation (codebreak300) https:\/\/clinicaltrials.gov\/study\/NCT05198934"},{"issue":"19","key":"10.1002\/14651858.CD014872.pub2-BIB0293|cit293","doi-asserted-by":"publisher","first-page":"4318","DOI":"10.1158\/1078-0432.CCR-24-1402","article-title":"Abiraterone, olaparib, or abiraterone + olaparib in first-line metastatic castration-resistant prostate cancer with DNA repair defects (Brcaaway)","volume":"30","author":"Hussain","year":"2024","journal-title":"Clinical Cancer Research"},{"issue":"16 Suppl","key":"10.1002\/14651858.CD014872.pub2-BIB0294|cit294","doi-asserted-by":"publisher","first-page":"5018","DOI":"10.1200\/JCO.2022.40.16_suppl.5018","article-title":"BRCAAWAY: a randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) with DNA repair defects","volume":"40","author":"Hussain","year":"2022","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0295|cit295","unstructured":"BRCAAWAY: a randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) with DNA repair defects https:\/\/clinicaltrials.gov\/study\/NCT03012321#study-overview"},{"issue":"17","key":"10.1002\/14651858.CD014872.pub2-BIB0296|cit296","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"New Englnad Journal of Medicine"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0297|cit297","unstructured":"Study of encorafenib + cetuximab plus or minus binimetinib vs. irinotecan\/cetuximab or infusional 5-fluorouracil (5-FU)\/folinic acid (FA)\/irinotecan (FOLFIRI)\/cetuximab with a safety lead-in of encorafenib + binimetinib + cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer (BEACON CRC) https:\/\/clinicaltrials.gov\/study\/NCT02928224"},{"issue":"1","key":"10.1002\/14651858.CD014872.pub2-BIB0298|cit298","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.clcc.2022.12.003","article-title":"Adverse events associated with encorafenib plus cetuximab in patients with BRAFV600E-mutant metastatic colorectal cancer: an in-depth analysis of the BEACON CRC study","volume":"22","author":"Taieb","year":"2023","journal-title":"Clinical Colorectal Cancer"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0299|cit299","unstructured":"Trial of different drug and treatment combinations for patients who are considering further therapy to treat their ovarian cancer https:\/\/www.isrctn.com\/ISRCTN14784018"},{"issue":"1","key":"10.1002\/14651858.CD014872.pub2-BIB0300|cit300","doi-asserted-by":"publisher","first-page":"e041463","DOI":"10.1136\/bmjopen-2020-041463","article-title":"Randomised phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer (OCTOVA): a study protocol","volume":"11","author":"Mansouri","year":"2021","journal-title":"BMJ Open"},{"issue":"6","key":"10.1002\/14651858.CD014872.pub2-BIB0301|cit301","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/s41416-023-02567-6","article-title":"Results of a randomised phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer","volume":"130","author":"Nicum","year":"2024","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0302|cit302","unstructured":"Initiative for molecular profiling and advanced cancer therapy (IMPACT II) https:\/\/clinicaltrials.gov\/study\/NCT02152254"},{"issue":"1","key":"10.1002\/14651858.CD014872.pub2-BIB0303|cit303","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41698-021-00159-2","article-title":"Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study","volume":"5","author":"Tsimberidou","year":"2021","journal-title":"NPJ Precision Oncology"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0304|cit304","unstructured":"An efficacy study comparing ZD6474 to placebo in medullary thyroid cancer https:\/\/clinicaltrials.gov\/study\/NCT00410761"},{"issue":"2","key":"10.1002\/14651858.CD014872.pub2-BIB0305|cit305","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial","volume":"30","author":"Wells","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD014872.pub2-BIB0306|cit306","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s41016-023-00329-0","article-title":"PTPRZ1-METFUsion GENe (ZM-FUGEN) trial: study protocol for a multicentric, randomized, open-label phase II\/III trial","volume":"9","author":"Bao","year":"2023","journal-title":"Chinese Neurosurgical Journal"},{"issue":"6 Suppl","key":"10.1002\/14651858.CD014872.pub2-BIB0307|cit307","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1200\/JCO.2022.40.6_suppl.040","article-title":"First results of the PROMPT trial: precision oncology allocation in patients with early castration-resistant prostate cancer following routine molecular profiling","volume":"40","author":"Kloots","year":"2022","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0308|cit308","unstructured":"Implementing routine molecular characterization in patients with metastatic castration resistant prostate cancer by NGS (PROMPT) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04746300"},{"issue":"7","key":"10.1002\/14651858.CD014872.pub2-BIB0309|cit309","doi-asserted-by":"crossref","first-page":"e395","DOI":"10.1016\/j.cllc.2022.05.009","article-title":"Biomarker-driven studies with multi-targets and multi-drugs by next-generation sequencing for patients with non-small-cell lung cancer: an open-label, multi-center, phase II adaptive umbrella trial and a real-world observational study (CTONG1702;CTONG1705)","volume":"23","author":"Yan","year":"2022","journal-title":"Clinical Lung Cancer"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0310|cit310","unstructured":"An open-label, multi-center, phase II umbrella study to assess efficacy of targeted therapy or immunotherapy directed by next generation sequencing (NGS) in Chinese patients with advanced NSCLC (TRUMP) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03574402"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0311|cit311","unstructured":"TRUMPRWS: a non-interventional study on genetic variants and its clinical relevance in Chinese patients with advanced NSCLC (TRUMPRWS) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03605602"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0312|cit312","unstructured":"A prospective randomized trial comparing the effectiveness of physician discretion guided therapy versus physician discretion guided plus next-generation sequence directed therapy https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02132845"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0313|cit313","unstructured":"A real-world study to explore and evaluate individualized targeted agents for patients of digestive cancers based on molecular characteristics after standard therapy failure in China https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04584008"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0314|cit314","unstructured":"Precision medicine randomized clinical trial comparing molecular tumor board assisted care to usual care https:\/\/clinicaltrials.gov\/study\/NCT05254795"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0315|cit315","unstructured":"A umbrella study in relapsed\/refractory peripheral T-cell lymphoma guided by molecular subtypes https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05559008"},{"issue":"5","key":"10.1002\/14651858.CD014872.pub2-BIB0316|cit316","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"Journal of the National Cancer Institute"},{"issue":"12","key":"10.1002\/14651858.CD014872.pub2-BIB0317|cit317","doi-asserted-by":"crossref","first-page":"773\u20138","DOI":"10.1038\/s41571-019-0262-9","article-title":"Phase I trials as valid therapeutic options for patients with cancer","volume":"16","author":"Adashek","year":"2019","journal-title":"Nature Reviews. Clinical Oncology"},{"issue":"20","key":"10.1002\/14651858.CD014872.pub2-BIB0318|cit318","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer","volume":"380","author":"Andre","year":"2019","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0319|cit319","doi-asserted-by":"crossref","first-page":"2940\u201350","DOI":"10.1200\/JCO.2013.53.5633","article-title":"Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG (0522)","volume":"32","author":"Ang","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"17","key":"10.1002\/14651858.CD014872.pub2-BIB0320|cit320","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1158\/1078-0432.CCR-15-1211","article-title":"Emerging agents and new mutations in EGFR-mutant lung cancer","volume":"12","author":"Ayeni","year":"2015","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0321|cit321","doi-asserted-by":"publisher","first-page":"16890","DOI":"10.1136\/bmj.l6890","article-title":"Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline","volume":"368","author":"Campbell","year":"2020","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0322|cit322","unstructured":"Cancer mortality for all cancer combined UK statistics - Cancer mortality 2017 www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type"},{"issue":"3","key":"10.1002\/14651858.CD014872.pub2-BIB0323|cit323","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","article-title":"The Functional Assessment of Cancer Therapy scale: development and validation of the general measure","volume":"11","author":"Cella","year":"1993","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD014872.pub2-BIB0324|cit324","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1634\/theoncologist.2014-0143","article-title":"Approval after phase I: ceritinib runs the three-minute mile","volume":"19","author":"Chabner","year":"2014","journal-title":"Oncologist"},{"issue":"4","key":"10.1002\/14651858.CD014872.pub2-BIB0325|cit325","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/jamaoncol.2022.7826","article-title":"Estimates and projections of the global economic cost of 29 cancers in 204 countries and territories from 2020 to 2050","volume":"9","author":"Chen","year":"2023","journal-title":"JAMA Oncology"},{"issue":"0","key":"10.1002\/14651858.CD014872.pub2-BIB0326|cit326","doi-asserted-by":"crossref","first-page":"100625","DOI":"10.1016\/j.eclinm.2020.100625","article-title":"Cost-effectiveness of cancer drugs: comparative analysis of the United States and England","volume":"29","author":"Cherla","year":"2020","journal-title":"EClinical Medicine"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0327|cit327","first-page":"3059","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"27","author":"Cheson","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0328|cit328","doi-asserted-by":"publisher","DOI":"10.4324\/9780203771587","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"1988"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0329|cit329","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eclinm.2020.100487","article-title":"When should we order a next generation sequencing test in a patient with cancer?","volume":"25","author":"Colomer","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"22","key":"10.1002\/14651858.CD014872.pub2-BIB0330|cit330","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"De Bono","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD014872.pub2-BIB0331|cit331","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/leu.2012.336","article-title":"Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group","volume":"27","author":"De Larrea","year":"2013","journal-title":"Leukemia"},{"issue":"8","key":"10.1002\/14651858.CD014872.pub2-BIB0332|cit332","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S1470-2045(10)70130-3","article-title":"Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis","volume":"11","author":"De Roock","year":"2010","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0333|cit333","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1016\/j.ejca.2008.09.013","article-title":"Her2-positive breast cancer: herceptin and beyond","volume":"18","author":"Dean-Colomb","year":"2008","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0334|cit334","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/9780470693926.ch15","volume-title":"Systematic Reviews in Health Care: Meta-Analysis in Context","author":"Deeks","year":"2001"},{"issue":"15 suppl","key":"10.1002\/14651858.CD014872.pub2-BIB0335|cit335","first-page":"e1882","article-title":"Real-world trends in costs of next generation sequencing (NGS) testing in US setting","volume":"39","author":"Desai","year":"2021","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD014872.pub2-BIB0336|cit336","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"17","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"issue":"14","key":"10.1002\/14651858.CD014872.pub2-BIB0337|cit337","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD014872.pub2-BIB0338|cit338","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"D\u00f6hner","year":"2010","journal-title":"Blood"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0339|cit339","unstructured":"European Cancer Information System: Cancer statistics https:\/\/ecis.jrc.ec.europa.eu accessed 29\/Nov\/2024"},{"issue":"2","key":"10.1002\/14651858.CD014872.pub2-BIB0340|cit340","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0341|cit341","unstructured":"What study designs can be considered for inclusion in an EPOC review and what should they be called? EPOC resources for review authors, 2021 epoc.cochrane.org\/epoc-resources-review-authors"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0342|cit342","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/978-1-4939-8973-7_4","volume-title":"Cell-Free DNA As Diagnostic Markers","author":"Fici","year":"2019"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0343|cit343","volume-title":"Methods Guide for Effectiveness and Comparative Effectiveness Reviews","author":"Fu","year":"2008"},{"issue":"9","key":"10.1002\/14651858.CD014872.pub2-BIB0344|cit344","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/s41416-021-01502-x","article-title":"Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study","volume":"125","author":"Gambardella","year":"2021","journal-title":"British Journal of Cancer"},{"issue":"3","key":"10.1002\/14651858.CD014872.pub2-BIB0345|cit345","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"73","author":"Bray","year":"2024","journal-title":"A Cancer Journal for Clinicians"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0346|cit346","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2021"},{"issue":"5","key":"10.1002\/14651858.CD014872.pub2-BIB0347|cit347","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.bja.2019.08.015","article-title":"Use of the GRADE approach in systematic reviews and guidelines","volume":"123","author":"Granholm","year":"2019","journal-title":"British Journal of Anaesthesia"},{"issue":"12","key":"10.1002\/14651858.CD014872.pub2-BIB0348|cit348","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1038\/s41591-022-02109-2","article-title":"Global and regional estimates of orphans attributed to maternal cancer mortality in 2020","volume":"28","author":"Guida","year":"2022","journal-title":"Nature Medicine"},{"issue":"25","key":"10.1002\/14651858.CD014872.pub2-BIB0349|cit349","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"3","key":"10.1002\/14651858.CD014872.pub2-BIB0350|cit350","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s41416-020-01140-9","article-title":"FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial","volume":"124","author":"Heinemann","year":"2021","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0351|cit351","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"357","author":"Higgins","year":"2003","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0352|cit352","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0353|cit353","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook"},{"issue":"9","key":"10.1002\/14651858.CD014872.pub2-BIB0354|cit354","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMsa042220","article-title":"Risks and benefits of phase 1 oncology trials, 1991 through 2002","volume":"352","author":"Horstman","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"3.5","key":"10.1002\/14651858.CD014872.pub2-BIB0355|cit355","doi-asserted-by":"crossref","first-page":"CGE22","DOI":"10.6004\/jnccn.2021.7204","article-title":"Mapping the mutational landscape in patients with advanced malignancies enrolled in early phase clinical trials","volume":"20","author":"Kazmi","year":"2022","journal-title":"Journal of the National Comprehensive Cancer Network"},{"issue":"12","key":"10.1002\/14651858.CD014872.pub2-BIB0356|cit356","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1001\/jamainternmed.2018.4710","article-title":"Evaluating progression-free survival as a surrogate outcome for health-related quality of life in oncology: a systematic review and quantitative analysis","volume":"178","author":"Kovic","year":"2018","journal-title":"JAMA Internal Medicine"},{"issue":"13","key":"10.1002\/14651858.CD014872.pub2-BIB0357|cit357","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/S1470-2045(15)00188-6","article-title":"Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial","volume":"16","author":"Le Tourneau","year":"2015","journal-title":"Lancet Oncology"},{"issue":"15","key":"10.1002\/14651858.CD014872.pub2-BIB0358|cit358","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD014872.pub2-BIB0359|cit359","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer","volume":"386","author":"Li","year":"2022","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0360|cit360","doi-asserted-by":"crossref","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Medicine"},{"issue":"4","key":"10.1002\/14651858.CD014872.pub2-BIB0361|cit361","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD014872.pub2-BIB0362|cit362","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13073-019-0703-1","article-title":"Molecular profiling for precision cancer therapies","volume":"12","author":"Malone","year":"2020","journal-title":"Genome Medicine"},{"issue":"4","key":"10.1002\/14651858.CD014872.pub2-BIB0363|cit363","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jamaoncol.2018.1660","article-title":"Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology","volume":"1","author":"Marquart","year":"2018","journal-title":"JAMA Oncology"},{"issue":"9","key":"10.1002\/14651858.CD014872.pub2-BIB0364|cit364","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1158\/2159-8290.CD-16-1396","article-title":"High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial","volume":"7","author":"Massard","year":"2017","journal-title":"Cancer Discovery"},{"issue":"7","key":"10.1002\/14651858.CD014872.pub2-BIB0365|cit365","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10.1002\/14651858.CD014872.pub2-BIB0366|cit366","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group","volume":"31","author":"Mosele","year":"2020","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0367|cit367","unstructured":"Targeted cancer therapies www.cancer.gov\/about-cancer\/treatment\/types\/targeted-therapies\/targeted-therapies-fact-sheet"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0368|cit368","unstructured":"National Institutes of Health Common Terminology Criteria for Adverse Events v5.0 https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm"},{"issue":"6","key":"10.1002\/14651858.CD014872.pub2-BIB0369|cit369","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/jamaoncol.2015.6315","article-title":"Response rate as a regulatory end point in single-arm studies of advanced solid tumors","volume":"2","author":"Oxnard","year":"2016","journal-title":"JAMA Oncology"},{"issue":"1","key":"10.1002\/14651858.CD014872.pub2-BIB0370|cit370","first-page":"1","article-title":"The NCI-MATCH trial: lessons for precision oncology","volume":"15","author":"O\u2019Dwyer","year":"2023","journal-title":"Nature Medicine"},{"issue":"1","key":"10.1002\/14651858.CD014872.pub2-BIB0371|cit371","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13063-019-3664-1","article-title":"Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols","volume":"20","author":"Park","year":"2019","journal-title":"Trials"},{"issue":"24","key":"10.1002\/14651858.CD014872.pub2-BIB0372|cit372","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"issue":"1","key":"10.1002\/14651858.CD014872.pub2-BIB0373|cit373","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1038\/s41467-021-23394-4","article-title":"Cell-free DNA captures tumor heterogeneity and driver alterations in rapid autopsies with pre-treated metastatic cancer","volume":"12","author":"Pereira","year":"2021","journal-title":"Nature Communications"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0374|cit374","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2024"},{"issue":"2","key":"10.1002\/14651858.CD014872.pub2-BIB0375|cit375","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.cegh.2018.05.005","article-title":"Interpretation of subgroup analyses in systematic reviews: a tutorial","volume":"7","author":"Richardson","year":"2019","journal-title":"Clinical Epidemiology and Global Health"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0376|cit376","doi-asserted-by":"crossref","DOI":"10.1002\/9781119333784","volume-title":"Individual Participant Data Meta-Analysis for Healthcare Research","author":"Riley","year":"2021"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0377|cit377","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jclinepi.2019.10.014","article-title":"GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions","volume":"119","author":"Santesso","year":"2020","journal-title":"Journal of Clinical Epidemiology"},{"issue":"12","key":"10.1002\/14651858.CD014872.pub2-BIB0378|cit378","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2014-10-607341","article-title":"An international consortium proposal of uniform response criteria for myelodysplastic\/myeloproliferative neoplasms (MDS\/MPN) in adults","volume":"125","author":"Savona","year":"2015","journal-title":"Blood"},{"issue":"11","key":"10.1002\/14651858.CD014872.pub2-BIB0379|cit379","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1001\/jamaoncol.2016.2129","article-title":"Association of biomarker-based treatment strategies with response rates and progression-free survival in refractory malignant neoplasms: a meta-analysis","volume":"2","author":"Schwaederle","year":"2016","journal-title":"JAMA Oncology"},{"issue":"1","key":"10.1002\/14651858.CD014872.pub2-BIB0380|cit380","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41436-019-0618-7","article-title":"The complete costs of genome sequencing: a microcosting study in cancer and rare diseases from a single center in the United Kingdom","volume":"22","author":"Schwarze","year":"2020","journal-title":"Genetics in Medicine"},{"key":"10.1002\/14651858.CD014872.pub2-BIB0381|cit381","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JPT Vist GE Glasziou P Guyatt GH Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook"},{"issue":"8","key":"10.1002\/14651858.CD014872.pub2-BIB0382|cit382","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11864-020-00765-5","article-title":"Treatment of relapsed acute myeloid leukemia","volume":"21","author":"Thol","year":"2020","journal-title":"Current Treatment Options in Oncology"},{"issue":"16","key":"10.1002\/14651858.CD014872.pub2-BIB0383|cit383","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"6","key":"10.1002\/14651858.CD014872.pub2-BIB0384|cit384","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s40291-012-0009-0","article-title":"Molecular-based classification of acute myeloid leukemia and its role in directing rational therapy","volume":"16","author":"Wertheim","year":"2012","journal-title":"Molecular Diagnosis & Therapy"},{"issue":"1","key":"10.1002\/14651858.CD014872.pub2-BIB0385|cit385","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13045-019-0737-2","article-title":"Progress and challenges in HER2-positive gastroesophageal adenocarcinoma","volume":"12","author":"Zhao","year":"2019","journal-title":"Journal of Hematology & Oncology"},{"issue":"10","key":"10.1002\/14651858.CD014872.pub2-BIB0386|cit386","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD014872","article-title":"Next-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer","author":"Kazmi","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T16:23:25Z","timestamp":1777911805000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD014872.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,3,24]]},"references-count":386,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd014872.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,24]]}}}